- Open Access
Canadian practice guidelines for the treatment of children and adolescents with eating disorders
Journal of Eating Disorders volume 8, Article number: 4 (2020)
Eating disorders are common and serious conditions affecting up to 4% of the population. The mortality rate is high. Despite the seriousness and prevalence of eating disorders in children and adolescents, no Canadian practice guidelines exist to facilitate treatment decisions. This leaves clinicians without any guidance as to which treatment they should use. Our objective was to produce such a guideline.
Using systematic review, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, and the assembly of a panel of diverse stakeholders from across the country, we developed high quality treatment guidelines that are focused on interventions for children and adolescents with eating disorders.
Strong recommendations were supported specifically in favour of Family-Based Treatment, and more generally in terms of least intensive treatment environment. Weak recommendations in favour of Multi-Family Therapy, Cognitive Behavioural Therapy, Adolescent Focused Psychotherapy, adjunctive Yoga and atypical antipsychotics were confirmed.
Several gaps for future work were identified including enhanced research efforts on new primary and adjunctive treatments in order to address severe eating disorders and complex co-morbidities.
Plain English summary
The objective of this project was to develop Canadian Practice Guidelines for the treatment of children and adolescents with eating disorders. We reviewed the literature for relevant studies, rated the quality of the scientific information within these studies, and then reviewed this information with a panel of clinicians, researchers, parents and those with lived experience from across the country. The panel came up with a list of recommendations regarding specific treatments. These recommendations included strong recommendations for the provision of Family-Based Treatment, as well as care provided in a least intensive environment. Weak recommendations were determined for Multi-Family Therapy, Cognitive Behavioural Therapy, Adolescent Focused Psychotherapy, adjunctive Yoga, and atypical antipsychotics. The panel also identified several areas for future research including the development of new treatments for severe and complex eating disorders.
Eating disorders are common and serious conditions affecting up to 4% of the population . The mortality rate, particularly for Anorexia Nervosa (AN) is high [2, 3], and has been shown to increase by 5.6% for each decade that an individual remains ill [4, 5]. It is well-documented that interventions targeted at earlier stages of illness are critically important, given the evidence showing that earlier treatment leads to better outcomes [6, 7]. Despite the seriousness and prevalence of eating disorders in children and adolescents, no Canadian practice guidelines exist to facilitate treatment decisions. This leaves clinicians without any guidance as to which treatment they should use. We systematically reviewed and synthesized the knowledge available on treatments for children and adolescents with eating disorders to develop our guidelines.
Review of existing guidelines
In the United States, practice parameters have been published by the American Academy of Child and Adolescent Psychiatry for youth with eating disorders . These parameters reflect good clinical practice rather than making statements as to the strength of the evidence to support the recommendations. Clinical practice guidelines have also been developed by the National Institute of Health and Care Excellence , however, grading of the evidence is also not presented in these guidelines. The Academy for Eating Disorders has also published guidelines on their website that focus on medical management, but do not focus on psychotherapeutic/psychopharmacological interventions, nor the strength of the evidence (http://aedweb.org/web/downloads/Guide-English.pdf). In summary, guidelines that are currently available tend to focus on medical stabilization, and neglect psychotherapeutic/psychopharmacological approaches to treating eating disorders. Furthermore, they do not rate the strength of evidence. No Canadian guidelines focused on eating disorders in the pediatric age group exist.
Our aim was to synthesize the best available evidence on treatments for children and adolescents with eating disorders resulting in the production of a practice guideline. The research questions to drive this knowledge synthesis were discussed by our research team and guideline development panel, and are listed below.
What are the best treatments available for children and adolescents diagnosed with eating disorders?
How effective is Family-Based Treatment for Anorexia Nervosa?
How effective is Family-Based Treatment for Bulimia Nervosa?
How effective is Cognitive Behavioural Therapy for Bulimia Nervosa?
How effective is Dialectical Behaviour Therapy for Bulimia Nervosa?
How effective are Atypical Antipsychotics for Anorexia Nervosa?
How effective are Selective Serotonin Reuptake Inhibitors for Bulimia Nervosa?
How effective is day treatment for any type of eating disorder?
How effective is inpatient treatment for any type of eating disorder?
We used systematic review of the literature to arrive at a knowledge synthesis of the best treatments for children and adolescents with eating disorders. This was followed by a grading of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [10,11,12]. These evidence profiles were then presented to a panel of stakeholders from across Canada, followed by a voting system and arrival at consensus on the recommendations. The Appraisal of Guidelines, Research, and Evaluation (AGREE II) tool was used to inform guideline development and reporting .
Criteria pertaining to study validity: i) meta-analyses, randomized controlled trials, open trials, case series, and case reports,
Criteria pertaining to the subjects: i) involving children and adolescents (under age 18 years), ii) with eating disorders (Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise Specified, Other Specified Feeding and Eating Disorder, Avoidant/Restrictive Food Intake Disorder, Binge Eating Disorder),
Criteria pertaining to the intervention: i) focusing on treatments including, but not limited to, Family-Based Treatment, Cognitive Behavioural Therapy, Dialectical Behavioural Therapy, Atypical Antipsychotics, Selective Serotonin Reuptake Inhibitors, Day Treatment, and Inpatient Treatment,
Criteria pertaining to the Outcome: i) weight (along with variants of weight such as BMI, treatment goal weight (TGW), etc.), ii) binge/purge frequency, iii) psychological symptoms such as drive for thinness, weight/shape preoccupation, and
Articles written in any language.
Exclusion criteria included: i) studies involving primarily adults (18 years or above), ii) studies focusing on medical management, iii) studies focusing on medical outcomes such as bone density, heart rate, iv) studies examining medical treatments such as hormone therapy, calcium, nutrition therapy, v) studies examining other medications. These exclusion criteria were developed for several reasons. We wanted to focus on treatments that were psychopharmacological and psychological in nature, along with outcomes that were central to the core features of eating disorders. We were trying to keep things as simple as possible when thinking of outcomes, especially with the goal of trying to combine studies in a narrative summary or even in a meta-analysis if possible. We focused on a couple of core outcomes with these goals in mind, so therefore excluded papers focusing on other physical outcomes (although these outcomes may indeed be related to weight status).
Identifying potentially eligible studies
A literature search was completed using the following databases: Medline, PsycINFO, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL. The references of relevant articles obtained were also reviewed. This was an iterative process, such that search terms were added based on developing ideas and articles obtained.
Literature search strategy
Initially, an environmental scan of existing guidelines for children and adolescents with eating disorders was completed by the core research team using search terms “guidelines” and “eating disorders” in children and adolescents. Our library scientist then designed and executed comprehensive searches in the databases listed above to obtain evidence to align with each of the guideline questions. The searches included a combination of appropriate keyword and subject heading for each concept. The sample search strategy included, but was not limited to, various combinations of the following terms as appropriate for the questions being addressed: Anorexia nervosa OR bulimia nervosa OR eating disorder not otherwise specified OR other specified feeding and eating disorder OR avoidant/restrictive food intake disorder; AND family-based treatment OR cognitive behavioural therapy OR dialectical behavioural therapy OR atypical antipsychotics OR selective serotonin reuptake inhibitors OR day treatment OR day hospital OR inpatient treatment. The search string was developed further and was modified for each database as appropriate. The search strategy was completed in August 2016. The screening and reviewing process then ensued. Some treatments emerged as important through our search strategy that were not initially identified by our research team and guideline panel as interventions to evaluate. We later included these treatments through panel discussions.
Forward citation chaining
In November 2018 we used a forward citation chaining process to search each included article to see if it had been cited by any additional articles since August 2016 up until November 2018. We then screened the newly found articles to decide whether to include them. The forward chaining process involved the use of Google Scholar to locate all articles citing our included articles from the primary search.
Grey literature was also reviewed, including conference proceedings from the International Conference on Eating Disorders dating back the last 10 years (2008–2018). Databases of ongoing research were searched including The Cochrane Central Register of Controlled Trials (CENTRAL). We also hand searched the International Journal of Eating Disorders from the last 10 years for relevant articles (2008–2018).
Applying eligibility criteria and extracting data
Two team members independently evaluated the results generated by our searches and came to consensus on which studies met eligibility criteria. We used the software Endnote and DistillerSR to organize our studies. DistillerSR was used for article screening and data extraction. Duplicate records identifying the same study were removed. Titles and abstracts were used to exclude obviously irrelevant reports by two reviewers. Potentially relevant articles were reviewed in full text by two reviewers who had to agree on inclusion, with a third resolving disputes. Authors of publications were contacted if any ambiguity existed about inclusion or exclusion. Data abstraction included the number of subjects, sex and/or gender of subjects, age range, type of treatment, type of control group if any, methodology (blinding, allocation concealment, intent-to-treat analysis), types of outcomes, and results. Sex was defined as biological sex, categorized into male or female. Gender was defined as the individual’s self-identified gender role/identity, categorized as girl, boy, or transgendered.
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system explicitly describes how to rate the quality of each study, as well as how to synthesize the evidence and grade the strength of a recommendation [10,11,12]. Using this system, we developed an evidence profile of each included study that detailed all of the relevant data about the quality and strength of evidence for that particular study. Each evidence profile was created using GRADEpro software. We then used the GRADE system to synthesize and classify the overall quality of evidence for each intervention based on the quality of all of the studies using that intervention combined, taking into account risk of bias, inconsistency, indirectness, imprecision, publication bias, dose-response, and effect size. Although we looked at each outcome independently, when the rating of the evidence was the same, we collapsed the outcomes in the GRADEpro tables for the sake of efficiency.
The Appraisal of Guidelines, Research, and Evaluation (AGREE II) tool is an international standard of practice guideline evaluation that was used to inform our guideline development and reporting, and was developed by a co-author (MB) . The Guideline Implementability for Decision Excellence Model (GUIDE-M) is a recent model that identifies factors to create recommendations that are optimally implementable . We used these models to guide our methodological processes in the development of our practice guideline.
The guideline team
The Guideline Team was comprised of a core research team and a larger guideline development panel (GDP). The core team presented the research questions to the GDP, reviewed evidence summaries, formulated practice recommendations, drafted the guideline, and limited biases that could impeach upon the guideline development process [17,18,19]. The chair of the GDP (MB) is an expert in guideline development having produced the AGREE framework . She is a non-expert in the field of eating disorders, and as such, was an impartial chair. She led the consensus discussions of the GDP and she oversaw conflict-of-interest disclosures and management. A multidisciplinary GDP of 24 diverse stakeholders from across Canada was established including members from academic centres who are experts in the field of eating disorders, multi-disciplinary front-line clinicians/knowledge users from community settings, parent and patient representatives, hospital administrators, and policy-makers (all authors on this guideline).
An initial teleconference was held on May 18, 2016 with the core research team and the GDP to confirm the research questions prior to starting the systematic reviews. The initial teleconference oriented GDP members to the guideline development process, the roles and responsibilities of the GDP, as well as reviewed all conflicts of interest. The research questions were refined, the clinical population and outcomes were discussed, and the target audience reviewed.
Once the reviews were completed and the evidence profiles were generated, an in-person meeting was held at a central location on December 20, 2018. The core research team presented their evidence profiles for discussion with the GDP. The in-person meeting focused on a facilitated discussion of the evidence profiles and draft recommendations generated by the core team. For each question, the panel reviewed the evidence, and discussed: i) whether the interpretation of the evidence put forward by the core team aligned with that of the GDP, ii) strengths and limitations of the evidence base, iii) considerations of the generalizability of the studies, precision of the estimates, and whether the evidence aligned with values and preferences of Canadian patients and clinicians. Alternative interpretations and suggestions for further research were discussed. Minority or dissenting opinions were noted. Issues regarding implementability of the recommendations were considered, and suggestions for dissemination of the guideline were elicited.
Following the in-person meeting, GDP members were provided with the draft guidelines for review and approval. Group consensus on recommendations and strength of recommendations was obtained using a modified Delphi method , with voting by all GDP members using an anonymous web-based survey platform, Lime Survey (www.limesurvey.com). For a recommendation to be approved, at least 70% of the GDP were required to identify their agreement with the recommendation . Consensus was achieved in the first round of voting. The GDP agreed to review and update the guideline every 5 years.
The purpose of the external review was to add validity to our guideline, but also initiate the dissemination process and elicit suggestions for dissemination and implementation. We invited review from four clinical and research experts in the area of pediatric eating disorders. Upon receiving external review, a summary of the review comments and suggestions was circulated to the GDP, along with a final version of the guideline for approval. The panel again discussed and voted on the changes suggested by the reviewers which included the addition of one further recommendation.
Three thousand, five hundred and twenty-two abstracts were identified for review within the family therapy section of our guideline (see PRISMA flow diagram, Fig. 1). Nineteen additional abstracts were identified through citation chaining (up to November 23, 2018) and review of reference lists. Two additional papers were identified through external review. After duplicates were removed, abstracts screened, and full text articles reviewed, 74 studies were included within the family therapy section of our guideline.
Of all treatments examined, Family-Based Treatment (FBT), in which parents are placed in charge of the refeeding process, had the most evidence to support its use in children and adolescents with Anorexia Nervosa (AN). One meta-analysis  and three high quality RCTs have demonstrated that greater weight gain and higher remission rates are achieved in FBT compared to individual treatment, especially when looking at 1 year follow up [6, 22, 23] (Table 1). One RCT compared a similar behavioural family systems therapy to Cognitive Behavioural Therapy (CBT) and found no significant differences , however the sample size was small (Table 1).
In terms of nonrandomized studies, a case-control study of 34 patients treated with FBT compared to 14 treated with “nonspecific therapy” indicated that those in FBT made greater gains in body weight and were less likely to be hospitalized . Seven case series (223 patients) also showed improvement in weight following treatment with FBT [26,27,28,29,30,31,32]. Eleven additional case reports (number of total patients = 29) are described showing benefit of FBT in terms of weight gain [33, 35,36,37,38, 40,41,42,43,44]. Some of these focus on twins [35, 42, 44], comorbid conversion disorder , FBT in a group home setting , FBT started on a medical unit , and FBT combined with medication .
Parent-Focused Family Therapy; a type of FBT in which most of the session is spent with the parents alone, may be just as effective as traditional FBT where the family is seen together [45,46,47] (Table 2).
Three high quality RCTs for Bulimia Nervosa (BN) have been completed and compared FBT to varying groups [48,49,50]. When FBT was compared to CBT, remission rates were significantly higher in the FBT group (39% versus 20%) . Remission rates were also significantly better in the FBT group compared to supportive psychotherapy (39% versus 18% ). However, when family therapy (with some elements consistent with FBT) was compared to guided self-help CBT, there were no significant differences (10% versus 14%) . The adolescents in this study were slightly older and had the option to involve a “close other” rather than a parent, which may have resulted in lower remission rates. A case series and case report also support the use of FBT for BN [34, 51] (Table 3).
Family-based treatment with other populations
Family-Based Treatment has been used for children and adolescents with atypical AN . This case series of 42 adolescents who were not underweight but had lost a significant amount of weight, indicated that there were significant improvements in eating disorder and depressive symptoms, but no improvement in self-esteem (Table 4).
Two case reports describe the application of FBT for children with Avoidant/Restrictive Food Intake Disorder (ARFID) [53, 54]. These case reports (n = 7 cases total) indicate that weight improved in all cases (Table 4).
Family-Based Treatment and other family therapies for children and adolescents with eating disorders across the gender spectrum, including those who are gender variant or nonconforming requires more study. However, there is one case report describing the application of FBT with a transgendered youth, along with complexities that arose  (Table 4).
Adaptations to family-based treatment for anorexia nervosa
Adaptations to FBT, such as shorter or longer treatment , removal of the family meal , guided self-help , parent to parent consult , adaptive FBT involving extra sessions and another family meal , short term intensive formats [61, 62] and delivery of FBT by telehealth [63, 64], appear promising, but require more study (Table 5).
Adjuncts to family-based treatment for anorexia nervosa
Adjuncts to FBT, in which additional treatments have been added to FBT, such as cognitive remediation therapy versus art therapy , parental skills workshops  and Dialectical Behavioural Therapy (DBT)  for children and adolescents with AN show promise, but require further study (Table 6).
Cognitive Behavioural Therapy has also been added as an adjunct to FBT for young patients with AN or BN. For AN, three case series [70,71,72] and two case reports [73, 74] indicate improved weight and psychological symptoms with added modules on perfectionism or exposure (Table 7). For BN, one case control study exists that compared one patient treated with FBT plus CBT to another patient treated with FBT alone, finding that both patients improved in terms of binge/purge symptoms and Eating Disorder Examination (EDE) scores  (Table 8).
One large high quality RCT (n = 169) found that Multi-Family Therapy (MFT) conferred additional benefits compared to single family therapy (FT) in terms of remission rates for adolescents with AN (75% in MFT versus 60% in FT), although no differences were found on the EDE . There is one case control study examining MFT versus treatment as usual (TAU) in 50 female adolescents with AN . Those in the MFT group had a higher percent body weight (99.6%) versus the TAU group (95.4%) at the end of the study. Two case series have also demonstrated a benefit of MFT for adolescents with AN [78, 79], and one case series with a mixed sample of adolescents with AN or BN showed benefit in psychological symptoms . There is also one small case series examining MFT for adolescents with BN that found improvements in eating disorder symptoms  (Table 9).
Other forms of family therapy
Systemic Family therapy has been used in one RCT  and three case reports [83,84,85] for AN. The high quality RCT compared Systemic Family Therapy to FBT and found no significant differences in terms of remission rates, however, rate of weight gain was greater in the FBT group and the use of hospitalization was also significantly lower in the FBT group (Table 10). Structural Family Therapy has been studied within two case series [86, 87] and two case reports [88, 89]. Remission rates in the case series were 75% (38/51) by clinical impression (Table 11). Both of these types of family therapy (Systemic and Structural) might be helpful for children and adolescents with AN, but the evidence generally does not indicate superiority to FBT, especially when costs are taken into consideration.
When looking at other nonspecific, family therapies in which family dynamics were examined, there is one high quality RCT which compared family therapy plus TAU to TAU alone  and three case reports [91,91,93] indicating a benefit of family therapy (Table 12). Family therapy has also been compared to family group psychoeducation with no significant differences in outcomes . Both groups were recruited through an inpatient program. Both groups gained weight and were receiving other forms of treatment including medical monitoring and nutritional advice, in addition to the interventions of interest (Table 13).
Emotion focused family therapy (EFFT) was compared in a randomized trial to CBT for 13 adolescents with BN  (Table 14). No differences were found in terms of binge/purge symptoms or psychological symptoms at the end of the study, however, the study was likely underpowered to detect differences.
Individual and group outpatient psychotherapies
Twelve thousand and eleven abstracts were identified in our database searches for the individual and group psychotherapy section of our guideline (see PRISMA flow diagram, Fig. 2). Twenty-five were added with forward chaining up to November 21, 2018, and 15 more through reference list review. Nine thousand, two hundred and eight abstracts were excluded during the abstract screening phase, and a further 1457 were excluded based on full article review, leaving a total of 48 articles included.
Cognitive Behavioural therapy
A small RCT (n = 22) did not show any difference between CBT and Behavioural Family Therapy (similar to FBT) in terms of weight, or psychological symptoms on the EDE for children and adolescents with AN, however, both groups improved  (Table 15). One large case series  indicated that CBT resulted in weight gain and improvement in eating disorder psychological symptoms for children and adolescent with AN (n = 49). Eight additional case reports [97,98,99,100,101,102,103,104] support these results as well. Improvements have also been shown when CBT is delivered in a group setting for AN in a case control design involving 22 patients , and in a case series of 29 adolescents  (Table 16).
For BN, three high quality RCTs were found examining CBT (Table 17). One RCT compared CBT to psychodynamic therapy in primarily adolescents, but also some young adults. This trial did not find any difference in terms of remission from BN. There were small differences in terms of a greater reduction in binge-purge frequency in the CBT group . There were also two high quality RCTs identified comparing CBT to family-based approaches for BN [49, 50]. There are conflicting results between these two studies, with the study by Le Grange and colleagues  indicating significantly greater remission rates in the FBT group compared to the CBT group, whereas the study by Schmidt and colleagues  showed no significant difference between the groups with only a small proportion remitted in each group. Two large case series indicate significant decreases in binge-purge frequency pre to post treatment [108, 109]. Several case reports indicating improvement in binge-purge symptoms exist [110,111,112,113,114].
Avoidant/restrictive food intake disorder
There were 13 case reports identified in which CBT was used to treat ARFID [115,116,117,118,119,120,121,122,123,124,125,126,127]. One of these described the delivery of CBT by telemedicine . One case described the combined treatment of CBT with fluoxetine for a significant choking phobia . Although these reports are preliminary, improvements in food avoidance were noted in all cases (Table 18).
Adolescent focused psychotherapy
Adolescent Focused Psychotherapy (AFP: based on psychodynamic principles) [22, 23, 128] and other psychodynamic treatments  have some evidence to support their use (Table 19). Remission rates were not significantly different between AFP and FBT in two RCTs involving a total sample of 158 adolescents with AN [22, 23]. Rates of 20% (12/60) remitted in AFP compared to 34% (21/60) in FBT were found in a study by Lock and colleagues , whereas 41% in the AFP group met the weight goal of the 50th percentile in a study by Robin and colleagues  compared to 53% in the FBT group. Differences between AFP and FBT became more apparent at 1 year follow-up with FBT demonstrating an advantage . Group analytic psychotherapy also has some evidence to support its use for AN  (Table 20). Psychodynamic Therapy (group or individual) for AN may be beneficial, however other treatments have some advantages over psychodynamic therapy in terms of cost and more rapid improvement in symptoms.
Dialectical Behavioural therapy
Dialectical Behavioural Therapy (DBT) for eating disorders has been applied for youth with AN, BN, Eating Disorder Not Otherwise Specified (EDNOS) and Binge Eating Disorder (BED) with promising results [131,132,133]. Two case series report decreases in binge-purge symptoms, and improvements in psychological eating disorder symptoms [131, 133], along with reductions in frequency of self-harm in multi-diagnostic youth  (Table 21).
Cognitive Remediation Therapy (CRT) has been mentioned in the family therapy section of this guideline as an adjunct to FBT , however, it has also been studied as an adjunct to other therapies in a case series  and a case report  for AN (Table 22). It has been used in multiple settings and will be touched upon again within the level of care section of this guideline.
One high quality study suggests some benefits of adjunctive yoga in terms of psychological symptoms of eating disorders, as well as depression and anxiety . In this study, 50 girls and 4 boys were randomly assigned to an 8-week trial of yoga plus standard care versus standard care alone. The majority of the participants had AN (29/54), and others were diagnosed with BN (9/54) and EDNOS (15/54). Eating disorder symptoms measured by the EDE decreased more significantly in the yoga group. Both groups demonstrated maintenance of body mass index (BMI), along with decreases in anxiety and depression scores (Table 23).
Two hundred and thirty-six abstracts were identified through database searching for the atypical antipsychotic section of our guideline (see PRISMA flow diagram Fig. 3). Seven additional articles were found through citation chaining and reference list review. After excluding 97 abstracts and then excluding 73 full text articles we arrived at 32 included studies for the atypical antipsychotic section. We then divided up the antipsychotics into their respective categories – Olanzapine, Risperidone, Quetiapine, and Aripiprazole.
Olanzapine has been the most commonly studied psychotropic medication for children and adolescents with AN (Table 24). At present, only one double blind placebo-controlled trial in this population has been published. Kafantaris and colleagues  examined olanzapine in 20 underweight adolescents being treated in inpatient (n = 9), day treatment (n = 6) and outpatient (n = 5) settings (age range 12.3 to 21.8 years). In a 10-week pilot study, they found no differences in beneficial effect between the olanzapine and placebo groups in the 15 subjects who completed the trial; however, the treated group showed a trend towards increasing fasting glucose and insulin levels by the end of the study. The mean dose of olanzapine was 8.5 mg daily. Of note, only 21% of eligible patients were recruited into the study and there was a high attrition rate. Although other research teams have also attempted RCTs using olanzapine in this population, trials have been hampered by a myriad of confounding and recruitment issues .
Three case control studies have examined the use of olanzapine in children and adolescents with AN [138,139,140]. The most recent of these studies enrolled 38 patients with AN; 22 of whom took olanzapine and 10 who declined medication and were retained as a comparison group . The mean dose of medication was 5.28 mg daily over a 12-week trial period. Those in the medication group demonstrated a significantly higher rate of weight gain in the first 4 weeks, although approximately one third of participants discontinued olanzapine early due to side effects . Norris and colleagues  completed a retrospective chart review of 22 inpatients treated with olanzapine compared to an untreated age-matched group. The rate of weight gain was not significantly different, however, the treated group had more psychiatric co-morbidities than those not taking olanzapine and experienced side effects of sedation and dyslipidemia . Hillebrand and colleagues  also reported on olanzapine use in seven patients (mean age 16.0 years) with AN. Most were taking 5 mg of olanzapine, with one patient receiving 15 mg once daily. The authors found reductions in activity levels in the adolescents taking olanzapine in comparison to 11 adolescents not treated with olanzapine. All patients were receiving either inpatient or day hospital care and there were no significant differences in weight .
In terms of case series, Leggero and colleagues  reported on 13 young patients (age 9.6 to 16.3 years) treated with a mean dose of 4.13 mg daily of olanzapine. Significant improvements were seen in weight, functioning, eating disorder symptoms and hyperactivity. Similarly, Swenne and Rosling  reported on 47 adolescents with AN treated with a mean dose of 5.1 mg daily. A mean weight gain of 9 kg was noted. The patients were treated for a mean of 228 days with olanzapine and were followed for three months following medication discontinuation. Biochemical side effects were closely monitored and were felt to be more related to refeeding processes than to medication .
Thirteen case reports (Table 24) have also been published [42, 143,144,145,146,147,148,149,150,151,152,153,154]. Pisano and colleagues  reported on five cases of adolescents with AN treated with 2.5 to 7.5 mg of olanzapine. At 6 month follow-up these patients demonstrated increased oral intake and improved BMI. Dennis, Le Grange, and Bremer  used olanzapine at a dose of 5 mg daily in five adolescent females with AN and found an increase in BMI, reduction of body concerns, and improvements in sleep and anxiety surrounding food and weight. Another case series involving four young patients aged 10 to 12 years reported on the use of olanzapine at a dose of 2.5 mg daily to treat AN . These authors reported improvements in compliance and weight gain, as well as decreases in agitation. Mehler et al.  reported on five female patients aged 12 to 17 years on a dose range of 5 mg to 12.5 mg daily of olanzapine. They found improvements in body image distortion and rigidity. La Via, Gray, and Kaye  described two females with AN who experienced reduction of inner tension and “paranoid ideas” with use of 10 mg daily of olanzapine. Finally, there is a case report using olanzapine 5 mg daily to treat a 17 year old girl with AN and co-morbid pervasive developmental disorder not otherwise specified . These authors reported weight restoration and improvements in eating behavior within 5 months of initiating treatment.
Eating disorder not otherwise specified
Avoidant/restrictive food intake disorder
In a recent case series, Spettigue and colleagues  described six patients with ARFID and co-morbid anxiety (median age 12.9 years) who were treated with a combination of family therapy plus pharmacotherapy (Table 26). All patients were treated with olanzapine in combination with other medications, making interpretation of the results difficult: three cases were treated with a combination of olanzapine and fluoxetine, one case was treated with olanzapine followed by fluvoxamine, and two cases were treated with a combination of olanzapine, cyproheptadine and fluoxetine. All six cases reached their treatment goal weights.
Another recent case series reported beneficial effects from olanzapine in the treatment of patients with ARFID . These authors completed a retrospective chart review and described a significant increase in weight, as well as improvements in anxiety and depressive symptoms in nine patients with ARFID treated with olanzapine. The mean final dose of olanzapine was 2.8 mg daily. All nine patients had comorbid mental health diagnoses including separation anxiety, obsessive-compulsive disorder, posttraumatic stress disorder, generalized anxiety disorder, and social anxiety disorder. Six of the nine also had significant major depressive symptoms.
The use of risperidone for AN has been studied in one high quality RCT and four case reports (Table 27). Hagman and colleagues  conducted a double-blind placebo-controlled trial of risperidone in adolescents and young adults with AN (age range 12 to 21 years). These authors randomized 40 patients to risperidone or placebo. The mean dose of risperidone was 2.5 mg daily over a mean duration of 9 weeks. There were no differences found between the groups at the end of the study . Personal communication with the primary author indicates that even when the subgroup of patients under age 18 years was examined, no differences were found. These authors concluded that their results do not support the use of risperidone in the weight restoration phase of treatment for young patients with AN .
Four case reports were found on the use of risperidone in the treatment of AN [159,160,161,162]. Weight generally increased in all four cases described, and willingness to eat increased. Of these was a case report of a 12 year old girl with autism and AN who is described as benefitting from treatment with risperidone at a dose of 0.5 mg twice daily . One of these cases describes the use of risperidone long-acting injection .
Avoidant/restrictive food intake disorder
Pennell and colleagues  described two cases of ARFID where significant weight loss occurred with stimulant treatment for Attention Deficit Hyperactivity Disorder (ADHD), resulting in the need for hospitalization. These cases were managed by temporarily stopping the stimulant and adding risperidone to help with appetite and behaviour (Table 28).
Very few studies could be found on the treatment of AN with quetiapine (Table 29). One case series described quetiapine use in three subjects, aged 11 to 15 years with severe AN (lengthy hospitalization, use of nasogastric tubes, and BMI 12.3 to 13.9) . Two of these patients were treated with quetiapine 100 mg twice daily, and one patient was treated with 250 mg twice daily. Authors reported improvements in body image disturbance, weight phobia, and “paranoid ideas”. Sedation and constipation were noted as side effects.
One case control study and two case reports were found on the use of aripiprazole in AN (Table 30). Frank and colleagues completed a retrospective case control study  and a case report  on the use of aripiprazole in adolescents with AN. The chart review described 22 adolescents with AN taking aripiprazole at a mean dose of 3.59 mg daily compared to an untreated comparison group of 84 adolescents with AN. These authors found a greater increase in BMI in the treated group . The case report described four adolescents who benefitted in terms of weight and improved eating disorder cognitions . One other case report was found on the use of aripiprazole . The adolescent received a dose of 5 mg daily. The authors report an improvement in anxiety and rigidity around eating with aripiprazole.
Avoidant/restrictive food intake disorder
Nine hundred and ninety-six abstracts were identified through our database searches along with six additional articles through citation chaining and reference list searching for the antidepressant section of our guideline (see PRISMA flow diagram Fig. 4). Six hundred and fifty-seven citations were excluded on screening. On full text review, 197 articles were excluded, leaving 19 papers for data extraction.
Selective serotonin reuptake inhibitors
In terms of Selective Serotonin Reuptake Inhibitors (SSRIs) for AN, one case control study and five case reports were found (Table 32). One retrospective study compared 19 adolescent patients with AN taking SSRIs to 13 patients with AN not treated with SSRIs . These authors found no differences between groups in terms of BMI, eating disorder psychopathology, or depressive and obsessive-compulsive symptoms after evaluating patients on admission, discharge and one-year follow-up. The SSRIs involved in this study included fluoxetine (n = 7, mean dose 35 mg daily), fluvoxamine (n = 8, mean dose 120 mg daily), and sertraline (n = 4, mean dose 100 mg daily).
Five adolescent case reports have been published on the use of SSRIs in AN. One of these focused on the use of sertraline in an adolescent with AN and symptoms of purging , another on the use of fluoxetine in an adolescent with AN and depressive features , and another on the use of fluoxetine for comorbid obsessive compulsive disorder . All of these cases described a benefit in terms of anxiety, mood and weight restoration. Two additional case reports examined SSRIs in combination with antipsychotics [151, 162]. Newman-Toker  described two cases of adolescents with AN in which risperidone (1.5 mg daily) was added to antidepressant treatment, with improvements in anxiety and weight gain. Similarly, Ercan and colleagues  described a case of a 15 year old female with severe AN treated with olanzapine, fluoxetine, alprazolam, and thioridazine, demonstrating that polypharmacy is sometimes needed for severe symptoms of AN including agitation and fear of weight gain. These authors also reported that once stabilized in terms of agitation, a maintenance dose of 10 mg of olanzapine daily resulted in an increase in BMI, along with a reduction of obsessive-compulsive symptoms, exercising, and eating disorder cognitions .
Selective serotonin reuptake inhibitors have been studied in children and youth with BN, although the evidence is scant (Table 33). One open trial of fluoxetine in ten adolescents aged 12 to 18 years  reported on 8 weeks of a titrating dose of fluoxetine (maximum 60 mg daily) along with supportive psychotherapy. Frequencies of binge episodes decreased significantly from a mean of 4.1 to zero episodes per week, and weekly purges decreased from 6.4 to 0.4 episodes per week . Seventy percent of patients were rated as improved or much improved on the clinical global impressions-improvement scale. No significant side effects were noted. Whether patients maintained these benefits over the long term is unknown.
One case report describes the use of valproate 200 mg twice daily following onset of mania felt to be related to the use of fluoxetine in an adolescent female with BN. In this report mood stabilized and binge eating and purging symptoms resolved once the fluoxetine had been stopped and valproate was initiated .
Other specified feeding and eating disorders
Our review identified one case report of a patient with Other Specified Feeding and Eating Disorder (OSFED), atypical AN, whose depressive symptoms were treated with escitalopram with improvement noted . She had lost almost 40 kg over a period of 4 months, but remained within a normal weight range (Table 34). Body image concerns remained.
Avoidant/restrictive food intake disorder
In terms of the ‘post-traumatic’ subtype of ARFID where there has been a choking event followed by refusal to eat and drink, the SSRIs have been described in case reports as being helpful (Table 35). Several SSRIs have been mentioned in case reports including; escitalopram  and fluoxetine [120, 178]. Of note, Celik and colleagues reported a case of two 2-year old twins who were treated with fluoxetine 5 mg daily for a severe posttraumatic food avoidance, with good effect . Similarly, a case series of three children with “severe choking phobias” were successfully treated with low-dose SSRIs (sertraline and paroxetine) . Spettigue and colleagues  also described the treatment of six children with ARFID treated with combinations of SSRIs and antipsychotics (described above in more detail in the olanzapine section).
Other antidepressants - mirtazapine
To date, one case control study as well as two case reports involving the use of mirtazapine in AN have been published (Table 36). Hrdlicka and colleagues  examined nine adolescent patients with AN who had been treated with mirtazapine for anxiety or depression compared to nine female controls with AN. The two groups were matched in terms of age and BMI. The mean dose of mirtazapine was 21.7 mg daily. There were no significant differences in terms of weight or BMI at the end of this study .
In terms of the case reports, the first case report described a 16 year old female hospitalized for AN and depression treated with mirtazapine . These authors found positive results in terms of weight restoration and mood improvement, and suggested further study of the medication was needed. More recently, Naguy and Al-Mutairi  described the case of a 16 year old boy hospitalized for severe AN who responded well to mirtazapine 30 mg/day in terms of weight restoration.
Avoidant/restrictive food intake disorder
For ARFID, mirtazapine has also been used to good effect, although the evidence is limited to one case series and one case report (Table 37). The case series described 14 cases with the rate of weight gain reported pre and post initiation of mirtazapine (average dose 25.5 mg daily) . Rate of weight gain was significantly greater after the initiation of the medication. An additional case report described the treatment of a 10 year old girl with ARFID and Obsessive-Compulsive Disorder (OCD). Anxiety and eating improved with 15 mg daily .
Lack of evidence
No studies could be found on the use of Selective Norepinephrine Reuptake Inhibitors (SNRIs) for this population. The same was true for Mood Stabilizers.
Level of care
The database search initially provided 7136 citations, as reported in the PRISMA flow diagram (Fig. 5). An additional 49 citations were added through review of references, and forward citation chaining. After removing the duplicates, 6426 records remained, of which 5881 were eliminated on screening given that they did not meet the inclusion criteria. Of the 545 full text articles assessed for eligibility, 440 full text articles were excluded because they were longitudinal follow-up studies, primarily adult studies, review or secondary analysis papers, book chapters or guidelines, did not provide sufficient description of the treatment provided, did not focus on inpatient treatment or otherwise did not meet the inclusion criteria. Ultimately, 105 studies were selected for inclusion in the level of care section of this guideline – 70 within the inpatient subsection, 29 within the day hospital subsection, and six within the residential subsection.
Twenty-one observational studies, none of which included control or comparison groups, have been published for a combined total of 1347 patients (Table 38) [184,185,186,187,188,189,190,191, 193,194,195,196, 198, 199, 201,202,203,204,205,206,207]. Various measures of change in weight were used across these studies including BMI, absolute weight in kg, percent Treatment Goal Weight (%TGW), weight gain per week and percent of patients attaining a predetermined discharge weight prior to discharge. Mean change in weight was positive in all studies. Mean length of stay ranged from 20.10 to 328.5 days.
While all of the observational studies of multimodal inpatient treatment reported on change in weight, fewer reported on change in eating disorder symptoms. Three studies (total n = 88) reported on Eating Disorders Examination-Questionnaire (EDE-Q) and one of the three studies reported significant change (n = 44, p < 0.05) [187, 201, 207]. This pre-post difference was attributed predominantly to the restraint and eating concerns subscales. Mean length of stay for these studies was between 203 and 115 days. Three studies (total n = 126) reported improvements in Eating Attitudes Test (EAT) scores at admission and discharge [186, 198, 203]. Length of stay varied between these three studies (29.8 days, 91 days and not reported). One study (total n = 44), with a mean LOS of 115 days reported on Eating Disorder Inventory (EDI) scores at admission and discharge . This study found no significant change in total or subscales of the EDI. One study reported on frequency of binge, laxative and exercise symptoms, however the total number of patients reporting these symptoms at admission was small (i.e. laxatives 0, bingeing 3, exercise 5) . Overall the study population was small (total n = 11 at admission and 7 at discharge). No statistical change was noted in any of these outcomes.
Although not a focus of our guideline, one study measured motivation for change using the Anorexia Nervosa Stage of Change Questionnaire (ANSOCQ) at admission and then again at discharge . The study included 49 patients whose mean length of stay was 30 days. Change in mean ANSOCQ score was noted to be statistically significant, however both admission and discharge scores fell into the “preparation” phase of motivation and the confidence intervals were wide.
Two studies of multimodal inpatient treatment were found which reported on weight gain during inpatient treatment for patients with mixed eating disorder diagnoses (Table 39). One study differentiated between patients with AN restricting type versus those with AN binge-purge type or BN , and the other differentiated between those with AN restricting type or AN binge-purge type versus those with BN or Eating Disorder Not Otherwise Specified binge-purge type (EDNOS-B/P) . Multimodal treatment was provided in both studies but varied between studies. Total number of patients studied was 150 across the two studies. In both cases there was a significantly greater increase in BMI for the group containing AN restricting type patients (total n = 94). In both cases this group started with a much lower BMI. Length of stay in these studies was approximately 6–7 months.
One of these studies compared symptom change using the EAT at admission to discharge in the group of patients with AN restricting type (n = 33) versus AN binge-purge type or BN (n = 29 ) . Overall there was a statistically significant improvement in EAT scores over the course of the admission. There was no significant difference in change on EAT by diagnosis.
Avoidant/restrictive food intake disorder
Four articles were found which reported on the inpatient treatment of a total of thirteen children treated using either a family-based or cognitive behaviour therapy approach [53, 208,209,210] (Table 40). Length of stay for these studies varied from 16 days to 60 days. In two of these studies weight gain was reported as an outcome and all patients gained weight [53, 208]. One of these studies reported on caloric intake in kcal/day which rose for all three patients . The third study reported on two cases of females ages 17 and 13 years who were “severely underweight” due to the onset of vomiting and food refusal . After admission, nasojejunum (NJ) tubes were placed to initiate refeeding when oral feeding was not tolerated. The authors reported that the use of an individualized behaviour plan for each patient providing reinforcements for eating was the critical factor which helped these patients to tolerate oral intake without vomiting and allowed for the removal of the NJ tubes.
Family-based inpatient care
There were three studies found examining inpatient treatment utilizing a family-based approach, one of which included 37 patients , and the other two studies which included one patient each (i.e. case reports) [39, 63] (Table 41). Length of stay in hospital was a mean of 20.6 weeks (SD = 13.6, range 3–58) in the first study  and 10 days in one case report  and unclear in the second case report . Mean weight gain was reported as 7.5 kg in the case series , a change in BMI from 16.32 to 17.5 in one case report , and a change in BMI of 15.4 to 19.5 in the other case report . In the case report by Goldfield and Boachie , the family received eight sessions of family-based informed therapy via telepsychiatry as one parent and siblings were not local.
CBT-based inpatient care
Three studies reported on inpatient treatment utilizing a CBT framework [197, 212, 213] (Table 42). These studies included two case series without a control group [197, 213] and one case study , for a total of 296 patients. Mean length of stay in these studies varied from 6 days to 90 days. In all studies patients gained weight in hospital.
One of these studies also reported on symptom change and included 238 patients . Global EDI score and all subscales showed significant improvements. Forty-five percent showed “clinically significant” changes in EDI Global Scores, 23.6% showed “reliable” changes, 28% of patients remained “unchanged” and 3.7% “deteriorated”.
Behaviour therapy based inpatient care
Fifteen studies reported on inpatient treatment utilizing a behaviour therapy approach (4 case series and 11 case reports ) [214,215,216,217,218,219,220,221,222,223,224,225,226,227,228] (Table 43). These studies included a total of 219 patients. Length of stay in these studies ranged from 13 days to 6.25 weeks [215, 217, 218]. In all studies patients gained weight.
Two of the case reports described change in intake as measured by kcal/day from admission to discharge. Only one of these studies reported the length of stay, which was 39 days. Calorie intake increased from 1600 kcal/d at admission to 3900 kcal/d at discharge in this study . The other study did not report the length of stay, but stated that intake increased from 850 kcal/d at admission to 1700 kcal/d at discharge .
Several studies reported on symptom change during admission to hospital. One case report described a decrease in purging after meals from 48% of meals/week to 0% of meals per week, although the length of stay for this patient was not noted . Two studies reported on EAT scores over the course of inpatient treatment. One was a case report describing that EAT scores remained high for the first 7 weeks of treatment and then dropped (from total score of 60 to 10) over the last 3 weeks of a 10-week admission . The other study measured EAT scores in 24 patients at admission and discharge (mean length of stay 11 weeks) and reported a change from total mean EAT of 37.1 at admission to 12.7 at discharge (p = 0.0001) .
Only one case series of 24 patients was found that examined inpatient treatment specifically for BN, and the treatment provided was based on behaviour therapy  (Table 44). The only eating disorder related outcome that was reported was weight. The mean LOS was 9.9 wks. (+/− 3.5 wks.). Weight decreased slightly over admission from a mean BMI of 20.6 to 20.5.
Psychodynamic based inpatient care
Only two reports of a total of six patients being treated as inpatients using a psychodynamic based approach were found [230, 231] (Table 45). The length of stay for these patients varied between 1.5 months and 5 months. Patients were reported to have gained between 1.3 kg/month to 6 kg/month while admitted.
Admission to pediatric unit
Four studies including a total of 200 patients, examined the effect of admission to a pediatric unit in terms of weight change in hospital [232,233,234,235] (Table 46). These studies did not include comparator groups and included patients with AN, BN and EDNOS. Mean length of stay varied between studies from 31 days to 85 days. In all studies weight improved.
Inpatient adjunctive treatments
Adjunctive multi-family/parent group therapy
One study with total 112 patients with various eating disorder diagnoses reported on symptom change as measured by the EDI during admission to a multimodal inpatient eating disorders unit in two groups of patients; those who received adjunctive multi-family group therapy (MFT, n = 62) and those who received adjunctive multi-parent group therapy (MPT, n = 50)  (Table 47). Both MPT and MFT interventions “promoted an autonomy-supportive parental attitude and the adolescents’ autonomy and self-determination.” Parents were encouraged to “create the conditions supporting their daughters’ autonomy in establishing healthy eating at home to indirectly increase their daughters’ motivation”. Affected children were only included in the MFT group. Group format was one introductory 3-h session followed by five 2-h sessions every 2 weeks. Measures were taken pre/post of the intervention. Patients were not randomized, but rather were allocated to MFT versus MPT depending on the time of admission. Results reported a main effect of time on drive for thinness (p < 0.001) and body dissatisfaction (p < 0.001) as measured by EDI. Both scales improved independent of type of intervention. A separate case series of 32 inpatient adolescents (29 with AN, 3 with BN) described improvements in EDI score pre-post delivery of Family-Oriented Group Therapy .
Three studies were found that examined the effect of meal support/supervision as part of inpatient treatment for groups of patients with mixed eating disorders diagnoses [238,239,240] (Table 48). There were no significant differences between cohorts who received meal support and those who did not on the rate of weight gain per day or week, although there was a trend towards greater weight gain in the group who received meal support. One of these studies reported on the difference in the rate of nasogastric tube (NGT) feeds in the cohort of patients treated on inpatient unit before the institution of consistent meal support versus after . Eight of 12 patients not receiving meal support (66.7%) and 1 of 9 (11.1%) of those receiving meal support required NGT feeds as part of inpatient admission, which was a statistically significant difference.
Selective versus non-selective menus
One study was found which included 22 patients with AN who received non-selective menus compared to 18 patients who received selective menus as part of their multimodal inpatient treatment  (Table 49). Length of stay varied between groups (although non-significantly) with patients on non-select menus remaining in hospital a mean of 60.3 (+/− 22.8) days vs 74.2 (+/− 28.7) days in the selective menus group. The non-selective menu group gained a significantly greater amount of weight. No significant differences were found on the EDE.
Bright light therapy
Anorexia nervosa and major depressive disorder
One study of patients with AN and depressive symptoms admitted to a CBT-based inpatient program and treated adjunctively with Bright Light Therapy was found  (Table 50). In this study patients were randomized to receive either daily 30 min Bright Light Therapy (BLT) + inpatient treatment (n = 12) for 6 weeks or inpatient treatment only for 6 weeks (n = 12). Patients in both groups had a significant change in their BMI during the 6-week study, however change from baseline was statistically significant by week 3 (p = 0.038) in BLT group versus by week 6 (p = 0.048) in the comparison group.
Cognitive remediation therapy
Four studies reported on the addition of Cognitive Remediation Therapy (CRT) to multimodal inpatient treatment [243,244,245,246] (Table 51). One study described change in weight between patients who received 10 sessions of CRT over 10 weeks versus those who received TAU in a quasi-experimental design (n = 24 in each group) . Both groups gained weight at a similar rate. The other studies reported on patients (total 79 patients) who received either 4 or 10 sessions of CRT provided as once weekly sessions. In all three studies patients gained weight. Given the design of these last three studies it was not possible to determine whether CRT had an impact on weight above and beyond what would have been expected by inpatient treatment alone.
Several studies of CRT added to inpatient treatment for AN reported on symptom change. One study included a description of two patients who received 10 sessions of CRT over 10 weeks in addition to multimodal inpatient treatment . Scores on EAT decreased for one patient (30 to 16) and increased in the other patient (35 to 36). One study, including 125 hospitalized patients , received either group (n = 55) or individual (n = 70) CRT. Only those patients receiving individual CRT completed the EDE-Q pre-post. Patients receiving individual CRT did not experience a change in their EDE-Q global score over the course of the 10 weeks they received CRT. One additional case report describes 10 sessions of CRT delivered to an inpatient with AN. Improvements on the EAT were observed .
One study, comprising 70 hospitalized patients who received multimodal inpatient treatment along with 10 individual sessions of CRT over 10 weeks reported on change in motivation as measured by the Motivational Stages of Change for Adolescents Recovering from an Eating Disorder (MSCARED) . Patients completed the MSCARED before and after the course of CRT. There was a statistically significant improvement in motivation noted. Due to the design of this study it was not possible to differentiate the effect of inpatient treatment alone from inpatient treatment plus CRT.
Inpatient and day treatment combined
Five reports on 265 patients with AN treated as inpatients followed immediately by day treatment were found [200, 248,249,250,251] (Table 52). In all five studies, patients were treated as inpatients and then transferred to day treatment once medically stable. Details regarding the number of hours/days spent in day treatment were not thoroughly reported, although mean length of stay varied from 7.9 weeks to 3.9 months. Weight change was reported in various ways, however, all studies indicated improvement in weight.
Symptom change was reported using various scales in these studies. One study included 35 patients with a mean length of stay of 15.1 weeks . Change in EDI total, drive for thinness and body dissatisfaction were not significantly different between admission and discharge. One study included 26 adolescents who received 13 weeks of inpatient treatment based on the Cognitive Behavioural Therapy- Enhanced (CBT-E) model followed by 7 weeks of Day Treatment Program (DTP) . EDE scores decreased significantly pre-post for global score and all subscales other than Shape Concern. This study also reported on frequency of eating disorder symptoms. Binge eating was present in eight patients (30%) at admission and only two patients (7.7%) at discharge. Purging by vomiting was present at admission for 10 patients (28.5%) and at discharge for 4 patients (15.1%). Laxative misuse was present for 3 patients at admission and none at discharge.
One study reported on change in motivation as measured by the ANOSCQ in 35 patients . These patients received 15.1 weeks of inpatient and day treatment. Overall scores increased a mean of 21.7 points, which signified moving from contemplation to preparation phases.
One study which included 71 patients who completed 7.9 weeks of combined inpatient and DTP (33 days inpatient and 22 days DTP) reported on “overall outcome” . At the end of DTP 35.2% were deemed to have an excellent outcome, 26.8% were deemed good outcome, 14.1% deemed below average outcome and 23.9% were deemed to have a poor outcome.
Admission to weight restoration versus short admission for medical stabilization with either FBT or day treatment
Two high quality studies examined the difference between patients randomized to receive a relatively short inpatient admission followed by either 20 sessions of FBT (n = 82)  or Day Treatment (n = 172)  compared to a lengthy inpatient stay to weight restoration (Table 53). In the Inpatient/FBT study  patients had all been unwell less than 3 years and in the inpatient/day treatment study  the patients were included only if it was their first admission. At the end of FBT or Day Treatment, there were no significant differences between those who were discharged after a short admission versus those who remained in hospital for weight restoration in terms of weight outcome, rate of readmissions over 12-month follow-up, or eating disorder symptoms [252, 253].
Multimodal day treatment
Two case series and one case report describe the outcomes of patients treated in their multimodal day hospital programs [254,255,256] (Table 54). Admission to day treatment in these studies could occur from an inpatient setting or an outpatient setting based on clinical need. Weight related outcomes were reported in various ways. Improvements in BMI from admission to discharge were described . Two studies reported improvements in %TGW at admission and discharge [255, 256]. One study reported an increase in weight from 81.6 to 84.2%TGW . The other study reported weight change separately for patients above and below 85%TGW at admission and found both cohorts gained weight . Mean length of stay varied between 70 to 92 days. One case report described a weight change from 87 lbs to 101 lbs over the admission to the day program .
One study examined eating disorder psychological symptoms with 26 patients remaining in DTP for mean length of 10 weeks . EDI scores for Drive for Thinness and Perfectionism improved significantly, whereas body dissatisfaction and maturity fears did not change significantly.
Two studies reported on percent of patients successfully completing the day treatment program [255, 256]. Definition of “successful completion” was based on a combination of symptom change, weight gain and progression in program (versus leaving against medical advice (AMA) or need for admission to an inpatient unit). Mean length of stay ranged from 11.6 to 15.3 weeks. Successful completion rates in these studies were 30 to 50%. One study examined whether completion rate varied between those that started at greater than or less that 85%TGW, and reported that there was no difference based on this factor .
Several studies address mixed diagnoses of eating disorders within a multimodal day hospital program [257,258,259,260,261] (Table 55). Weight in all studies improved over the course of day treatment. Weight gain was correlated with a diagnosis of AN or EDNOS (versus BN), longer length of stay and lower weight at admission . The length of stay in these studies varied between 15.3 weeks and 13.1 weeks.
Lazaro and colleagues  reported outcomes separately for those with AN and BN within their day treatment program. The sample size was 160 patients (116 AN patients and 44 BN patients). Mean length of stay was 15 weeks. For both groups, self-esteem improved in relation to others and in relation to weight and shape. No significant differences were found between the AN and BN groups .
Two studies treating mixed diagnoses of eating disorders for total of 61 patients looked at successful completion of the program [257, 258]. Success was defined using various criteria such as adequate weight gain, symptom reduction, and no AMA discharge or inpatient admission. Success rate was 49%  and 50% .
One study including 30 patients with mixed diagnoses examined motivational stage of change . Length of stay was 10.5 weeks. Motivational Stage of Change was measured pre-post with the MSCARED . Patients were noted to progress through the stages of change during treatment. The change in stage of change from intake to discharge was significantly correlated with the change in the Children’s Eating Attitudes Test (ChEAT) score during the same time period .
Family-based day treatment
Anorexia nervosa/low weight eating disorders
Nine studies for a total of 427 patients examined a family-based day treatment program [262,263,264,265,266,267,268,269,270] (Table 56). Studies varied with regards to the degree to which they included parents in treatment, number of hours/week of programming and length of stay. Criteria for admission to the day treatment program varied.
Five studies reported improvement in BMI [264, 265, 268,269,270]. Three studies reported on total weight gained in program [262, 263, 269]. Two studies reported on change in %TGW which rose from 83 to 93% in one study , and 83 to 98% in another study . Length of stay in these studies varied from 28 days to 1.3 years.
One study reported on difference in weight outcomes between their Maudsley and non-Maudsley DTP, noting no difference between these two groups . Another study reported on differences between patients who received “formal psychotherapy” (individual and/or family) outside of program thereby needing to leave program for approx 2 h/week and noted that patients who received external psychotherapy within the first 2 months of entering DTP gained significantly less weight . One study examined predictors of weight restoration in DTP and reported that higher BMI at admission, greater gain in the first 4 weeks and lower caregiver empowerment at baseline were predictive of weight restoration at end of intensive treatment .
Six studies examined psychological symptoms with the EDE-Q [264, 266, 267, 269,270,271]. EDE-Q scores, global and all subscales decreased significantly in these studies. In a study reporting on a control group which was treated in the same program, but without the inclusion of Maudsley/family interventions, the EDE-Q scores decreased more in the Maudsley group than the non-Maudsley . Of note the scores for Weight Concern and Restraint Concerns did not change significantly in the non-Maudsley group whereas they decreased significantly in the Maudsley group .
One study consisting of 32 patients reported on body image disturbance . Body image disturbance disappeared completely in 59%, decreased partially in 28% and remained unchanged in 13%. Prolonged duration of meals improved during treatment and “normalized” in 87.5% by end of treatment. Eighty-seven percent stopped ritualistic exercise habits by end of treatment.
One study including 60 patients, with median length of stay 8 months showed statistically significant change in EDI Drive for Thinness and body dissatisfaction . Statistically significant change was reported on the EAT.
Mixed eating disorder diagnoses
Five case series and one case report for total of 262 patients studied a family-based day treatment program with adolescents with mixed eating disorder diagnoses [272,273,274,275,276,277] (Table 57). Studies varied with regard to the form of parent involvement, hours/week in treatment and admission criteria. Four studies reported change in BMI from admission to discharge and found that BMI improved [272, 275,276,277] (Table 57). Three studies reported on change in %TGW and found significant improvements [272, 274, 276]. One study reported weight change as 12/19 patients reaching 100%TGW at 3 months and the other 7/19 reaching a mean %TGW of 94% . The mean LOS varied between these studies from 3.2 weeks to 28.5 weeks. (Table 57).
In terms of psychological symptoms, one study with total of 51 patients looked at EDE-Q scores and found improvements . Two studies for a total of 82 patients reported on change in EDI [273, 275]. EDI drive for thinness subscale decreased in one study , and in the second study EDI scores were reported to have improved significantly on all subscales other than maturity fears by 3 months . One study examining ChEAT scores, involved 56 patients, however, only 30 patients had pre-post data to analyze. The mean length of stay was 10.3 weeks . ChEAT scores improved.
One study with 51 patients  examined a family therapy with group DBT skills training in an intensive outpatient program. Fifteen out of 36 patients (30%) were considered not successful due to need for higher level of care, psychiatric hospitalization or left treatment against medical advice.
One study was found with eight patients and their parents  describing family-based treatment with CBT principles within a DTP. Statistically significant decreases were seen in all subscales of the EDE-Q and the Yale Brown Cornell Eating Disorder Scale (YBC-EDS) total score decreased significantly  (Table 57).
Avoidant/restrictive food intake disorder
One study examined 32 patients with ARFID, compared to patients with AN (n = 68), BN (n = 15) and OSFED (n = 15) in the same DTP  (Table 58). This study reported that the reason for patients with ARFID to be admitted to their day treatment program was “acute onset of severe food restriction that results in significant weight loss or failure to gain weight.” Length of stay for ARFID patients was significantly shorter than for those with AN, but not compared to those with BN or OSFED. Patients with ARFID gained weight from 86% median BMI to 95% median BMI which did not differ from the median weight gain for the AN or OSFED groups (Table 58). This study also reported that patients with ARFID had total ChEAT scores that were subclinical at admission and demonstrated minimal change in scores during treatment. There were no significant differences between the diagnostic groups at the end of treatment on ChEAT scores .
Family-based day treatment combined with dialectical Behavioural therapy
One study including 35 adolescent females with BN examined DBT combined with FBT principles within a day hospital setting  (Table 59). Length of stay was 77.18 days. Binge-purge symptoms monitored via self-report on EDE-Q decreased significantly . EDE-Q global, shape and weight concerns decreased significantly pre-post, whereas restraint and eating concerns scores were unchanged at end of treatment .
CBT- based day treatment
One case series including 42 patients with AN examined a CBT- based day treatment program  (Table 60). Length of stay in day treatment was a mean of 22.2 weeks. Patients gained weight, with a mean increase of 5.37 kg or BMI increase of 1.87 kg/m over the course of treatment (Table 60). It was noted the increase in weight was correlated with the number of months in program, as well as EDI scores and Motivational Stages of Change score. Of note only 38 completed 2 months, 25 completed 4 months and 9 completed 6 months of treatment.
Behaviour therapy based day treatment
Avoidant/restrictive food intake disorder
Two case reports were found describing patients aged 4 years (fear of choking)  and 8 years (emetophobia) . Length of stay in the day treatment program was 9 days and 7 days respectively. At the end of treatment, the patients had increased their intake (Table 61). The 4 year old was no longer supplement dependent and accepting 30 new foods. The 8 year old had increased her intake from having nothing by mouth to meeting her daily nutritional needs.
Resistance training as an adjunct in a day treatment program
This randomized controlled study involved 36 patients with mixed diagnoses of eating disorders (18 intervention and 18 control) . The study took place within a day treatment program and consisted of supervised exercise (50–60 min), for 3 days per week for 8 weeks. In order to be included in the study the patients must have had a BMI greater than 14 and could not be “excessive exercisers” (ie < 6 h per week). Intervention patients received resistance training plus 150 kcal extra to compensate for this activity. There was no difference in weight restoration between groups (Table 62).
Four case series examined residential treatment and included 1068 patients with AN, BN and EDNOS, along with two additional case reports (Table 63). One case series examined patients with AN exclusively . Reasons for admission to residential treatment were not noted and all studies took place in the United States. These studies measured change in weight in various ways. Four studies utilized BMI [284,285,286,287]. Admission mean BMI varied from 15.8 to 18.6. Discharge mean BMI varied from 17.8 to 21.3. Change in mean BMI from admission to discharge varied from 1.92 to 2.72. Two studies additionally reported on %TGW at admission and discharge. Admission mean %TGW were 83.4%  and 76.7%  and discharge mean %TGW were 94.7 and 86.6% respectively.
One study reported on 361 patients that were purging at admission a mean of 3.25 times per day . At discharge, they were purging a mean of 0.02 times per day. Differing diagnostic groups were not reported separately. Length of stay was an average of 52 days. Treatment was multimodal.
In terms of psychological symptoms, three studies looked at EDI scores and included 313 patients with AN, BN and EDNOS [285,286,287]. The treatment provided was multimodal. Length of stay varied between studies from 28.5 to 56.4 days. In general, EDI scores were improved when admission scores were compared with discharge scores. One study looked at the EDE-Q pre to post and included 105 patients with AN, BN and EDNOS . The EDE-Q changed from 3.6 (SD = 1.58) to 1.95 (SD = 1.35).
One study including 65 patients with AN examined readiness for change. Treatment was multimodal . Mean readiness for change (ANSOQC) at admission was 53.98 (SD 16.36) and at discharge was 67.28 (SD 20.06). This difference was statistically significant, but does not signify a change in actual stage of change. Participants were further divided into low readiness and high readiness. High readiness patients had a shift from 66.86 (SD 11.78) at admission to 76.80 (SD 15.71) at discharge, signifying a shift from Preparation to Action Phases. Low readiness patients shifted from 40.70 (SD 7.12) to 57.47 (SD 19.5), signifying a shift from Contemplative to Preparation Phases.
Two case reports both described patients with AN and Type 1 diabetes and reported weight gains and better glycemic control after residential treatment [288, 289]. Varying types of treatment were provided in multimodal format.
Family-based treatment (FBT) is strongly recommended for any child or adolescent with Anorexia Nervosa or Bulimia Nervosa, especially for those who have been ill less than 3 years.
There are implementation challenges with Family-Based Treatment (FBT) including requirements for specialized, well-trained staff, access and costs of training. Parent-Focused Family Therapy – where the patient is seen separately from the family – may be just as effective as traditional FBT where the family is seen together. Adaptations to FBT such as shorter or longer treatment, removal of the family meal, guided self-help, parent to parent consult, short term intensive formats, and delivery of FBT by telehealth, require more study. Structural and Systemic Family therapy might be helpful for children and adolescents with Anorexia Nervosa, but the evidence generally does not indicate superiority to FBT, especially when costs are taken into consideration.
One meta-analysis  and three high quality RCTs [6, 22, 23] have demonstrated that greater weight gain and higher remission rates are achieved in FBT compared to individual treatment, particularly when focusing on one year follow-up. Eight large case series also show improvement in weight following treatment [26,27,28,29,30,31,32, 40].
Three high quality RCTs for Bulimia Nervosa have been completed and compared FBT to various control conditions [48,49,50]. When FBT was compared to Cognitive Behavioral Therapy (CBT), remission rates were significantly higher in the FBT group (39% versus 20%) . Remission rates were also significantly better in the FBT group, when FBT was compared to supportive psychotherapy (39% versus 18% ). However, when family therapy (with some elements consistent with FBT) was compared to guided self-help CBT, there were no significant differences in remission (10% versus 14%) . A case series and case report also support the use of FBT for Bulimia Nervosa [34, 51].
Multi-family therapy (MFT) may be a reasonable treatment option for children and adolescents with Anorexia Nervosa.
Multi-Family Therapy (MFT) provides workshops for multiple families at once and generally is delivered alongside single-family therapy following FBT principles, although some studies just report on the delivery of the multi-family workshops alone. It may be challenging for programs to run MFT as it requires several staff present for several full days and requires several families interested at the same time to begin the treatment. The delivery of MFT for children and adolescents with Bulimia Nervosa may be beneficial but requires more study. Members of the guideline committee indicated that the value of parents having support from each other cannot be understated. The panel voiced that peer support is often a missing component of treatment and hospital administration can place barriers to the implementation of this option.
One large high quality RCT found that MFT (multi-family workshops plus single FBT) conferred additional benefits compared to FBT alone in terms of remission rates in adolescents with Anorexia Nervosa (75% in MFT versus 60% in FBT) . Several case series have also demonstrated a benefit of MFT [77,78,79,80]. There is one small case series examining MFT for adolescents with Bulimia Nervosa which found improvements in eating disorder symptoms .
Additional promising therapies
Other outpatient family therapies exist that have some data showing their promise but where more research is required before definitive recommendations can be made. These are treatment options in which research efforts should be prioritized.
FBT for children with atypical Anorexia Nervosa.
FBT for children with Avoidant/Restrictive Food Intake Disorder (ARFID).
FBT for children across the gender spectrum, including individuals who are gender variant or gender non-conforming.
Adjuncts to FBT, such as cognitive remediation therapy, art therapy and cognitive behavioural therapy for children and adolescents with Anorexia Nervosa.
Emotion focused family therapy (EFFT) for Bulimia Nervosa and Anorexia Nervosa, as stand- alone treatment, or as an adjunct to FBT.
Individual or group outpatient psychotherapies
Cognitive Behavioural therapy
Cognitive behavioural therapy may be a reasonable treatment option for children and adolescents with Anorexia Nervosa or Bulimia Nervosa.
Across the studies, Cognitive Behavioural Therapy was not offered in a uniform manner. Motivational interviewing as a component of treatment or prior to initiating treatment, may also be helpful although strong scientific evidence is lacking due to a paucity of studies.
Eight case reports [97,98,99,100,101,102,103,104] and one large case series  indicate that CBT results in weight gain and improvement in eating disorder psychological symptoms for children and adolescents with Anorexia Nervosa. A small RCT (n = 22) did not show any difference between CBT and Behavioural Family Therapy in terms of these outcomes for children with Anorexia Nervosa, however, both improved . Efficacy has also been shown when CBT is delivered in a group setting for Anorexia Nervosa [105, 106].
For Bulimia Nervosa, three high quality RCTs exist examining CBT. One RCT compared CBT to psychodynamic therapy in primarily adolescents, but also some young adults. This trial did not find any difference in terms of remission from Bulimia Nervosa. There were small advantages in terms of greater reduction in binge/purge frequency in the CBT group . There are also two high quality RCTs comparing CBT to family-based approaches for Bulimia Nervosa [49, 50]. There are conflicting results between these two studies, with the study by Le Grange and colleagues  indicating significantly greater remission rates in the FBT group compared to the CBT group, whereas the study by Schmidt and colleagues  showed no significant difference between the groups with only a small proportion remitted in each group. Two large case series indicate significant decreases in binge/purge frequency pre to post treatment [108, 109]. Several case reports indicating improvement in binge/purge symptoms exist [110,111,112,113,114].
Adolescent focused psychotherapy
Adolescent focused psychotherapy may be a reasonable treatment option for children and adolescents with Anorexia Nervosa.
Adolescent Focused Psychotherapy (AFP) could be delivered in situations in which FBT has been attempted, but been ineffective, or if FBT is contraindicated, not possible, or not available.
A manual is not yet available to clinicians, which makes training and dissemination difficult.
It is a challenge to study this type of treatment due to its lengthy nature and lack of clarity around essential elements. Adolescent Focused Psychotherapy includes elements of: an emphasis on therapeutic relationship with a goal to improve symptoms, psychoeducation, the role of the eating disorder as a coping mechanism, along with the development of more positive coping mechanisms. Panel members agreed that treatment of this nature is commonly delivered and can be quite beneficial to some patients. This treatment for Anorexia Nervosa may be beneficial, however other treatments have some advantages in terms of cost and more rapid improvement in symptoms.
Adolescent Focused Psychotherapy (AFP; based on psychodynamic principles) has some evidence to support its use [22, 23, 128], as does individual psychodynamic treatment , and group analytic psychotherapy . Remission rates were not significantly different between AFP and FBT in two RCTs involving a total sample of 158 adolescents [22, 23]. Rates of 20% (12/60) remitted in AFP compared to 34% (21/60) in FBT were found in the study by Lock and colleagues , whereas 41% in the AFP group met the weight goal of the 50th percentile in the study by Robin and colleagues  compared to 53% in the FBT group. Differences between FBT and AFP become more apparent at one year follow up with FBT having an advantage .
Additional promising psychotherapies
Other promising outpatient psychotherapies exist that require more research before definitive recommendations can be made.
Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder.
Dialectical Behavioural Therapy for eating disorders.
Other therapies - adjunctive yoga
Yoga, in addition to standard treatments, may be a reasonable option for medically stable youth with Anorexia Nervosa, Bulimia Nervosa, and Other Specified Feeding and Eating Disorders.
There is no evidence to guide the specific regimen (e.g. duration, frequency) of yoga. Yoga should only be undertaken with support by the physician involved in the individual’s care. Hot yoga or other strenuous forms of Yoga are not recommended when medical concerns exist. If Yoga interferes with recovery, or worsens symptoms, it should be discontinued.
One high quality study suggests some benefits in terms of the psychological symptoms of eating disorders, as well as depressive and anxious symptoms in the context of an eating disorder .
The clinical trials environment to test medications for the treatment of eating disorders is fraught with ethical and methodological complexity. Obtaining the required informed consent to bring a child or adolescent into a study requires disclosure of the study intent, hypotheses, and potential for side effects attributable to the medication. In some cases, these effects (e.g. weight gain) are connected specifically to outcomes patients may strongly fear. In addition, parents are often reluctant to give their children psychotropic medication. This often results in studies that have prolonged enrollment phases, that struggle or fail to meet recruitment goals, and suffer from high rates of patient drop out. As a consequence, study quality is poor and prone to bias.
Olanzapine or aripiprazole may be reasonable treatment options for certain populations of children and adolescents with Anorexia Nervosa if monitored carefully.
In specific contexts, consideration of olanzapine and aripiprazole use may be undertaken for the adjunct treatment of low weight children and adolescents with Anorexia Nervosa. Although the evidence-base supporting these specific medications is scant and of poor quality, expert opinion suggests potential benefit in carefully selected treatment contexts. Given their propensity for side effects, these medications should only be considered with appropriate consultation and monitoring by trained specialists in Child and Adolescent Psychiatry or Pediatrics who have expertise in the treatment of children and adolescents with eating disorders. When utilized, these medications should be initiated at a very low dose (0.625–1.25 mg for olanzapine, or 0.5–1.0 mg for aripiprazole) and titrated very carefully. Target doses in research trials are often modest. Informed consent from the young person, or their substitute decision maker including risk of side effects must be obtained and appropriate monitoring undertaken while these medications are in use.
Olanzapine has been the most commonly studied psychotropic medication for children and adolescents with Anorexia Nervosa. At present, only one small double-blind placebo-controlled trial in this population has been published , and no beneficial effect in favour of olanzapine was found in the 15 subjects who completed the trial. Several open trials and case series have examined the use of olanzapine in children and adolescents with Anorexia Nervosa [138,139,140,141,142]. While some have demonstrated benefit (e.g. weight gain), reported adverse effects associated with the medication as well as patient attrition were common.
Additional promising medications
The use of other medications for the purposes of eating disorder treatment require more research before definitive recommendations can be made. These medications should be a priority for research. These include:
Selective Serotonin Reuptake Inhibitors (fluoxetine for Bulimia Nervosa).
Risperidone and Quetiapine for use in Anorexia Nervosa.
Atypical Antipsychotics for use in Avoidant/Restrictive Food Intake Disorder.
Mirtazapine use for patients with Anorexia Nervosa.
Medications that are not recommended
The medications below have no evidence to support their use in the treatment of primary eating disorder symptoms, or are harmful.
Selective Norepinephrine Reuptake Inhibitors – no evidence.
Mood Stabilizers - no evidence.
Buproprion - not recommended for use in eating disorders, due to the elevated risks of seizures in this population.
Level of care – inpatient/day treatment/residential care
In contrast to the above sections that examine specific treatment modalities, this section focuses on the level – or setting - where care takes place. Research on level of care is generally sparse. Moreover, the setting where care takes place is often conflated with the treatment activities themselves making it difficult to attribute which mechanism(s) contributed to outcomes. Some tools already exist to guide the practitioner on which level of care might be indicated (e.g. residential, inpatient, day treatment, or outpatient care) based on a variety of clinical factors .
Level of care
It is strongly recommended that the least intensive treatment environment be provided (e.g. family-based treatment or day treatment versus lengthy hospitalizations) especially for those children and adolescents with Anorexia Nervosa requiring a first admission to hospital and/or with a duration of illness less than 3 years.
Definitive clinical research does not currently exist that identifies the specific characteristics of what comprises “least intensive environment” or an agreed upon hierarchy of least to most intensive environments. However, the evidence-base does provide signals of reasonable options and areas that should be prioritized for further study. In addition, definitive clinical research does not currently exist that identifies the specific elements required to optimize inpatient, specialist outpatient, and community outpatient programs.
Studies comparing different levels of care and length of stay
One trial of 167 adolescents randomized to inpatient care, a specialist outpatient program, or a generalist community outpatient program found significant improvements across all three groups with no differences between the groups . In order to examine length of inpatient treatment related to outcome, two high quality studies examined the difference between patients randomized to receive a relatively short inpatient admission followed by either 20 sessions of FBT (n = 82)  or day treatment (n = 172)  compared to a lengthy inpatient stay to weight restoration. In the inpatient/FBT study  patients had all been unwell less than 3 years, and in the inpatient/day treatment study  the patients were included only if it was their first admission. At the end of FBT or day treatment, there were no significant differences between those who were discharged after a short admission versus those who remained in hospital for weight restoration in terms of: weight outcome, rate of readmissions over 12-month follow-up, or eating disorder symptoms.
Studies examining inpatient treatment only
Multiple low-quality studies have been published examining the outcomes for children and adolescents with eating disorders [187, 188, 193, 194, 197, 213, 216, 222, 224, 227, 232,233,234, 251, 292]. The most consistent finding is that inpatient treatment leads to weight restoration regardless of the treatment framework used. There are no studies directly comparing treatment modalities. Outcomes related to the cognitive symptoms of the eating disorder were mixed in these inpatient studies. Some low quality studies have examined various adjuncts to inpatient treatment including non-select versus selective menus, meal support, multi-family versus multi-parent group therapy, cognitive remediation therapy, and bright light therapy. Non-select menus conferred a benefit related to rate of weight restoration and meal support appeared to decrease the need for nasogastric tube feeds. Other outcomes were less evident and potentially eclipsed by the effect of the inpatient treatment milieu.
Studies examining day treatment programming only
Several low-quality studies report a benefit of day hospital programming in terms of weight restoration and reduction in eating disorder symptoms [255, 256, 258, 259, 262, 266, 272,273,274,275,276, 280]. Of these studies 14 described using a family-based approach [262, 264,265,266,267,268,269,270, 272,273,274,275,276,277], eight a multimodal approach [254,255,256,257,258,259,260,261] and one a CBT framework  in their programs. All studies reported an increase in mean weight during day treatment, and most studies reported improvement in eating disorder symptoms. One study compared cohorts in their program with and without family involvement , and found that weight outcomes did not vary with family involvement, but there was a greater improvement observed in overall symptomatology, and in particular weight concerns and dietary restraint with family involvement. Only three small studies have examined the use of day treatment settings for patients with Avoidant/Restrictive Food Intake Disorder [278, 281, 282] and one small study examined this setting for Bulimia Nervosa . One high quality study observed no harm with the addition of a standardized resistance training program to day treatment care as usual for patients with mixed eating disorder diagnoses .
Studies examining residential programming only
Six low quality studies examined outcomes for patients with eating disorders treated in a residential setting [284,285,286,287,288,289]. Studies included patients with Anorexia Nervosa, Bulimia Nervosa and Eating Disorder Not Otherwise Specified for a total of 1070 patients studied. Reasons for admission to residential treatment were not noted, there is a paucity of information reported on treatments received prior to admission to residential facilities, and all studies took place in the United States. Length of stay in these studies varied from 28 days to 56 days. All six studies reported that underweight patients gained weight during treatment. One study reported that episodes of purging were significantly reduced . Three studies reported that eating disorder symptoms decreased significantly during treatment in the residential setting [285,286,287].
General care considerations when choosing level or setting of treatment
The following are reasonable care considerations as it relates to the choice of environment in which treatment is available for children and adolescents with eating disorders.
Care within an inpatient treatment environment
Inpatient treatment may promote weight restoration regardless of model of care provided, but requires more study to determine the critical treatment elements related to weight restoration.
Cognitive Behavioural Therapy (CBT) and family-based inpatient treatment may lead to improvement in eating disorder symptoms.
Inpatient treatment combined with day treatment follow-up may be helpful in weight restoration, symptom change and motivation for children and adolescents with Anorexia Nervosa.
Adjuncts to inpatient treatment, such as non-selective menus, meal support, cognitive remediation and bright light therapy may be helpful for certain children and adolescents with eating disorders.
Inpatient treatment alone or in combination with day treatment for Bulimia Nervosa and Avoidant/Restrictive Food Intake Disorder requires more study.
Peer support during inpatient treatment by other parents would be an asset.
Preparing for discharge from inpatient care
Any transition in care is a period of high risk for deterioration and adverse events. Bridging these transitions with added supports is needed to prevent young people from suffering from adverse outcomes due to disruptions in continuity of care.
Parental support is needed in order to prepare parents for discharge and the treatment that follows.
Patient and parent preferences should be considered when planning for discharge.
Issues of consent and capacity should also be considered when making decisions around admission and discharge.
Care within a day treatment environment
Day treatment may promote weight restoration in Anorexia Nervosa regardless of model of care provided, but requires more study to determine the critical treatment elements related to weight restoration.
Multimodal, CBT and family-based day treatment may lead to improvement in eating disorder symptoms.
Day treatment for Avoidant/Restrictive Food Intake Disorder may be helpful in weight restoration and improved outcome.
Resistance training may be offered to children and adolescents who do not have a history of compulsive exercise while participating in day treatment, but it remains unclear whether this intervention imparts any benefit.
Day treatment varies significantly from study to study, so comparison is difficult. The common element appears to be a group-based treatment program with meal support.
Equity and access to day treatment are issues to be considered. Families must live close to such a program in order to be able to attend, or must abandon their home/career to move close to a day treatment program in order for their child to attend.
Care within a residential treatment program
Although literature was lacking to support a formal recommendation for residential treatment, many of the panel members opined that residential treatment is an essential component of treatment for some individuals with eating disorders who need lengthier treatment in a setting away from home. Based on expert opinion and those with lived experience, it was agreed that individuals who have had repeat admissions to the hospital and those with complex comorbid conditions, might benefit from residential treatment.
These are the first Canadian Practice Guidelines to evaluate the evidence on psychotherapeutic and psychopharmacological treatments focused specifically on children and adolescents with eating disorders. Strong recommendations were supported in favour of Family-Based Treatment, and more generally in terms of least intensive treatment environment. Weak recommendations in favour of Multi-Family Therapy, Cognitive Behavioural Therapy, Adolescent Focused Psychotherapy, adjunctive Yoga, and atypical antipsychotics were confirmed. Several gaps for future work were identified including enhanced research efforts on new adjunctive treatments in order to address severe eating disorders and complex co-morbidities. Underlying the specific treatments emerged some general values and philosophies to be upheld, particularly apparent during the panel meeting. These philosophies included mutual trust and respect in the provider/patient/family relationship.
In addition, parent and patient representatives mentioned the critical importance of peer support (patient and parent), particularly in times of transition between different levels of care and from the pediatric to adult system of care. The importance of a co-ordinated continuum of care from outpatient to residential care was emphasized by the panel. The lack of services was also emphasized. Several individuals mentioned the lack of residential care across the country and the great need that exists for certain individuals with eating disorders for intensive inpatient and residential services. This need is particularly apparent for those who are medically stable, but have psychiatric co-morbidities and need longer term treatment in a highly structured environment. The co-morbidity with substance abuse was mentioned as an area where there is a complete lack of services in Canada. Patient and parent choice/preferences of treatment were also mentioned as essential to consider when thinking of the treatments and levels of care available.
The strengths of this guideline are numerous. We used rigorous methodology for our literature review and synthesis as well as for our guideline development. Our literature synthesis methods included a thorough review of all literature (including gray literature and papers of any language). We translated 25 papers for full text review. In terms of guideline development, conflict of interest statements were reviewed by an impartial chair in order to address any biases. We had a face-to-face meeting to discuss our recommendations, followed by an anonymous voting procedure. Furthermore, our panel included the voices of various stakeholder groups including researchers, clinicians, policy makers, parents and those with lived experience.
These guidelines serve as a starting point for Canadian Practice Guidelines for treating children and adolescents with eating disorders, and as such, they have several limitations. Our guidelines did not aim to review treatments within the scope of medical stabilization, or in terms of treatments for the physical complications of eating disorders in children and adolescents. A companion Canadian Guideline focused on these topics for children and adolescents is needed. The reader is encouraged to examine the Academy for Eating Disorders Guidelines on eating disorders, and the Clinical Practice Guidelines for the BC eating disorders continuum of services which includes a Short Term Allocation Tool for Eating Disorders (STATED) , specifically outlining medical criteria for hospital admission, and level of care recommendations for the full age spectrum. None of the outpatient treatments mentioned in our current guideline should be delivered with a medically unstable child needing hospital admission for medical reasons. Similarly, if outpatient treatments are attempted, and an individual deteriorates during these treatments, or fails to progress, stepping up to either day treatment, or inpatient care may be needed. Furthermore, if outpatient treatments are not available, then lengthier inpatient stays may be necessary.
We did not examine qualitative literature in our search. The scope of our guideline was so broad already, that these studies could not be incorporated. These studies should be included in future iterations of these guidelines. Qualitative meta-syntheses on the topic of treatment for and recovery from AN in particular, highlight the importance of therapeutic alliance, treatment targets, building identity and self-acceptance [293, 294]. These qualitative works, can shed light on the concept of recovery which can have several different definitions, not just focused on symptomatic change, but quality of life, and functionality of work and relationships. For the purposes of this guideline, we focused on studies reporting on symptomatic change, however, future iterations should include other outcomes as viewed as essential to those affected by these illnesses and their families. Caregiver outcomes would also be important to include in future guidelines. We also would recommend including transition age youth as an important population with unique needs. A more in-depth examination of transitions in the health care system in general would be beneficial.
Most of the published studies to date on pharmacotherapy of eating disorders in children and adolescents have focused on the role of antipsychotic medication in AN. Despite progress in recent years, the total number of subjects studied remains small, and there is a paucity of randomized controlled trials. Further, it has become increasingly clear that there are substantive challenges involved with the completion of such studies. As a result, there is still insufficient evidence to recommend medication as a first line consideration in children and adolescents with eating disorders. Due to the significant challenges in recruitment and retention in clinical trials to date, large multi-site collaborative trials are necessary to move the field forward in determining which young patients with eating disorders might benefit most from psychotropic medication and in what fashion. In addition, we did not systematically review the literature for certain classes of medications including benzodiazepines, or stimulants. We came across a couple of case reports through searching in the other areas [295, 296], however, searches on these drugs should be included in future iterations of this guideline.
Our search strategy also had limitations. Although our search was very thorough, we were unable to retrieve several citations as full text articles. Some of these were difficult to locate as they were dissertations, conference proceedings, books, or simply did not exist. We attempted to examine sex differences, but the numbers of male subjects were so small that no conclusions could be drawn. Furthermore, although we searched the literature thoroughly for art and music therapies, we could not find any articles on these topics. In addition, two papers in the family-based therapy section were identified through external review, indicating that these papers were not found through the initial search.
Despite these limitations, these guidelines represent a significant step forward in developing a collaborative process for identifying effective treatments for children and adolescents with eating disorders and will be reviewed every 5 years.
Several gaps were noted by the guideline panel and these should be a focus for future study. These gaps included treatments for complex presentations of eating disorders, including complex co-morbidity such as borderline personality disorder, obsessive compulsive disorder, and substance use disorder. Determining which treatment benefits which individual in advance should be a priority for further study. There were also difficulties in making recommendations around medication use. Studies in the area of psychopharmacology are fraught with challenges in terms of a lack of recruitment and retention. Small and poorly designed studies, make it difficult to arise at recommendations. Perhaps multi-site trials, or innovative designs are needed to further promote and enhance the evidence base where psychopharmacology is concerned. The panel noted difficulty in making recommendations on inpatient and residential levels of care, but noted that these are sorely needed services, and should be expanded in Canada, along with a more rigorous investigation of effectiveness. Developing treatments, including new and adjunctive psychotherapeutic approaches for families unable to engage in Family-Based Treatment is essential. In addition, particular populations may have unique needs that have not yet been explored, such as predominantly male populations, and those with non-binary gender identities. Furthermore, creative ways of accessing evidence-based treatment need to be explored including the use of technology to treat patients and families at a distance.
Our Canadian Practice Guidelines for the treatment of children and adolescents with eating disorders recommend the provision of: 1) FBT for those with AN or BN (strong recommendation), 2) MFT for those with AN (weak recommendation), 3) CBT for those with AN or BN (weak recommendation), 4) AFP for those with AN (weak recommendation), and, 5) adjunctive Yoga for those with AN, BN and OSFED (weak recommendation). All of these treatments can only be delivered in a medically stable young person, and more intensive treatment should be considered if treatments are deeming to lack efficacy. In terms of medication, a weak recommendation was confirmed for olanzapine and aripiprazole for those with AN. A strong recommendation was agreed upon for providing care in a least intensive environment. Patient and parental preferences should be considered. Research efforts should be devoted to developing treatments for severe eating disorders with complex co-morbidity.
Availability of data and materials
Percent treatment goal weight
Attention deficit hyperactivity disorder
Adolescent focused psychotherapy
- AGREE II:
Appraisal of guidelines, research, and evaluation
Anorexia nervosa stage of change questionnaire
Avoidant/restrictive food intake disorder
Binge eating disorder
Bright light therapy
Body mass index
Cognitive behavioural therapy
Cognitive behavioural therapy - enhanced
Children’s eating attitudes test
Cognitive remediation therapy
Dialectical behavioural therapy
Day treatment program
Eating attitudes test
Eating disorder examination
Eating disorder examination - questionnaire
Eating disorders inventory
Eating disorder not otherwise specified
Emotion focused family therapy
Guideline development panel
Grading of recommendations assessment, development, and evaluation system
Guideline implementability for decision excellence model
Length of stay
Multi-parent group therapy
Motivational stages of change for adolescents recovering from an eating disorder
Obsessive compulsive disorder
Other specified feeding and eating disorder
Preferred reporting items for systematic reviews and meta-analyses
Selective norepinephrine reuptake inhibitors
Selective serotonin reuptake inhibitors
Treatment as usual
Yale brown Cornell eating disorder scale
Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. Int J Eat Disord. 2003;34(4):383–96.
Arcelus J, et al. Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68(7):724–31.
Ward A, et al. Follow-up mortality study of compulsorily treated patients with anorexia nervosa. Int J Eat Disord. 2015;48(7):860–5.
Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry. 1995;152(7):1073–4.
Herzog DB, Nussbaum KM, Marmor AK. Comorbidity and outcome in eating disorders. Psychiatr Clin North Am. 1996;19(4):843–59.
Russell GF, et al. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry. 1987;44(12):1047–56.
Treasure J, Russell G. The case for early intervention in anorexia nervosa: theoretical exploration of maintaining factors. Br J Psychiatry. 2011;199(1):5–7.
Lock J, et al. Practice parameter for the assessment and treatment of children and adolescents with eating disorders. J Am Acad Child Adolesc Psychiatry. 2015;54(5):412–25.
National Institute of Health and Care Excellence. Eating disorders: recognition and treatment. United Kingdom: the National Institute of Health and Care Excellence; 2017.
Guyatt GH, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–2.
Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
Jaeschke R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
Brouwers MC, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839–42.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester: Wiley; 2019.
Guyatt G, Rennie D. Users’ guides to the medical literature: a manual for evidence-based clinical practice. Chicago: American Medical Association; 2002.
Brouwers MC, et al. Validation of the guideline implementability for decision excellence model (Guide-M). BMJ Qual Saf. 2013;22(Suppl 1):A1–A94.
Eccles MP, et al. Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest. Implement Sci. 2012;7:60.
Kunz R, et al. Guideline group composition and group processes: article 3 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc. 2012;9(5):229–33.
Qaseem A, et al. Guidelines international network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525–31.
Yousuf MI. Using experts’ opinion through the Delphi technique. Pract Assess Res Eval. 2007;12(4):1–8.
Couturier J, Kimber M, Szatmari P. Efficacy of family-based treatment for adolescents with eating disorders: a systematic review and meta-analysis. Int J Eat Disord. 2013;46(1):3–11.
Robin AL, et al. A controlled comparison of family versus individual therapy for adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1482–9.
Lock J, et al. Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa. Arch Gen Psychiatry. 2010;67(10):1025–32.
Ball J, Mitchell P. A randomized controlled study of cognitive behavior therapy and behavioral family therapy for anorexia nervosa patients. Eat Disord. 2004;12(4):303–14.
Gusella JL, Campbell AG, Lalji K. A shift to placing parents in charge: does it improve weight gain in youth with anorexia? Paediatr Child Health. 2017;22(5):269–72.
Paulson-Karlsson G, Engstrom I, Nevonen L. A pilot study of a family-based treatment for adolescent anorexia nervosa: 18- and 36-month follow-ups. Eat Disord. 2009;17(1):72–88.
Lock J, et al. Is family therapy useful for treating children with anorexia nervosa? Results of a case series. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1323–8.
Le Grange D, Binford R, Loeb KL. Manualized family-based treatment for anorexia nervosa: a case series. J Am Acad Child Adolesc Psychiatry. 2005;44(1):41–6.
Loeb KL, et al. Open trial of family-based treatment for full and partial anorexia nervosa in adolescence: evidence of successful dissemination. J Am Acad Child Adolesc Psychiatry. 2007;46(7):792–800.
Goldstein M, et al. The effectiveness of family-based treatment for full and partial adolescent anorexia nervosa in an independent private practice setting: clinical outcomes. Int J Eat Disord. 2016;49(11):1023–6.
Couturier J, Isserlin L, Lock J. Family-based treatment for adolescents with anorexia nervosa: a dissemination study. Eat Disord. 2010;18(3):199–209.
Herscovici C, Bay L. Favorable outcome for anorexia nervosa patients treated in Argentina with a family approach. Eat Disord. 1996;4(1):59–66.
Le Grange D. Family therapy for adolescent anorexia nervosa. J Clin Psychol. 1999;55(6):727–39.
Le Grange D, Lock J, Dymek M. Family-based therapy for adolescents with bulimia nervosa. Am J Psychother. 2003;57(2):237–51.
Loeb KL, et al. Family-based treatment of a 17-year-old twin presenting with emerging anorexia nervosa: a case study using the “Maudsley method”. J Clin Child Adolesc Psychol. 2009;38(1):176–83.
Sim LA, et al. Family-based therapy for adolescents with anorexia nervosa. Mayo Clin Proc. 2004;79(10):1305–8.
Krautter T, Lock J. Treatment of adolescent anorexia nervosa using manualized family-based treatment. Clin Case Stud. 2004;3(2):107–23.
Aspen V, Boutelle K. Family-based treatment without a family: case report of an adolescent with anorexia nervosa. Eat Weight Disord. 2014;19(1):119–23.
Matthews A, Peterson CM. Intensive family-based therapy during an acute medical admission for anorexia nervosa: a case report. Clin Case Stud. 2016;15(4):313–25.
Turkiewicz G, et al. Feasibility, acceptability, and effectiveness of family-based treatment for adolescent anorexia nervosa: an observational study conducted in Brazil. Braz J Psychiatry. 2010;32(2):169–72.
O’Neil J, Terry R, Connelly S. Family-based approach to anorexia nervosa. Osteopath Fam Physician. 2012;4:168–71.
Duvvuri V, et al. Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. Int J Eat Disord. 2012;45(2):294–7.
Goldstein M, Madden S, Peters L. The use of effective treatments: the case of an adolescent girl with anorexia nervosa in the context of a conversion disorder. Clin Child Psychol Psychiatry. 2013;18(2):214–23.
Le Grange D, Schwartz S. Family therapy for identical twins with anorexia nervosa. Eat Weight Disord. 2003;8(1):84–7.
Eisler I, et al. Family therapy for adolescent anorexia nervosa: the results of a controlled comparison of two family interventions. J Child Psychol Psychiatry. 2000;41(6):727–36.
Le Grange D, et al. Randomized clinical trial of parent-focused treatment and family-based treatment for adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 2016;55(8):683–92.
Le Grange D, et al. Evaluation of family treatments in adolescent anorexia nervosa: a pilot study. Int J Eat Disord. 1992;12(4):347–57.
Le Grange D, et al. A randomized controlled comparison of family-based treatment and supportive psychotherapy for adolescent bulimia nervosa. Arch Gen Psychiatry. 2007;64(9):1049–56.
Schmidt U, et al. A randomized controlled trial of family therapy and cognitive behavior therapy guided self-care for adolescents with bulimia nervosa and related disorders. Am J Psychiatry. 2007;164(4):591–8.
Le Grange D, et al. Randomized clinical trial of family-based treatment and cognitive-behavioral therapy for adolescent bulimia nervosa. J Am Acad Child Adolesc Psychiatry. 2015;54(11):886–94 e2.
Dodge E, et al. Family therapy for bulimia nervosa in adolescents: an exploratory study. J Fam Ther. 1995;17:59–77.
Hughes EK, et al. A case series of family-based treatment for adolescents with atypical anorexia nervosa. Int J Eat Disord. 2017;50(4):424–32.
Spettigue W, et al. Treatment of children and adolescents with avoidant/restrictive food intake disorder: a case series examining the feasibility of family therapy and adjunctive treatments. J Eat Disord. 2018;6(20):1–11.
Murray SB, Thornton C, Wallis A. Selective eating in a 9-year-old boy: family therapy as a first-line treatment. Clin Child Psychol Psychiatry. 2013;18(2):270–5.
Strandjord SE, Ng H, Rome ES. Effects of treating gender dysphoria and anorexia nervosa in a transgender adolescent: lessons learned. Int J Eat Disord. 2015;48(7):942–5.
Lock J, et al. A comparison of short- and long-term family therapy for adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 2005;44(7):632–9.
Herscovici CR, Kovalskys I, Orellana L. An exploratory evaluation of the family meal intervention for adolescent anorexia nervosa. Fam Process. 2017;56(2):364–75.
Lock J, et al. Parental guided self-help family based treatment for adolescents with anorexia nervosa: A feasibility study. Int J Eat Disord. 2017;50(9):1104–8.
Rhodes P, et al. Can parent-to-parent consultation improve the effectiveness of the maudsley model of family-based treatment for anorexia nervosa? A randomized control trial. J Fam Ther. 2008;30:96–108.
Lock J, et al. Can adaptive treatment improve outcomes in family-based therapy for adolescents with anorexia nervosa? Feasibility and treatment effects of a multi-site treatment study. Behav Res Ther. 2015;73:90–5.
Rockwell RE, Boutelle K, Trunko ME, Joy Jacobs M, Kaye WH. An innovative short-term, intensive, family-based. treatment for adolescent anorexia nervosa: case series. Eur Eat Disord Rev. 2011;19(4):362–7.
Marzola E, Knatz S, Murray SB, Rockwell R, Boutelle K, Eisler I, Kaye WH. Short-term intensive family. therapy for adolescent eating disorders: 30-month outcome. Eur Eat Disord Rev. 2015;23(3):210–8.
Goldfield GS, Boachie A. Delivery of family therapy in the treatment of anorexia nervosa using telehealth. Telemed J E Health. 2003;9(1):111–4.
Anderson KE, et al. Utilizing telehealth to deliver family-based treatment for adolescent anorexia nervosa. Int J Eat Disord. 2017;50(10):1235–8.
Lock J, et al. Feasibility study combining art therapy or cognitive remediation therapy with family-based treatment for adolescent anorexia nervosa. Eur Eat Disord Rev. 2018;26(1):62–8.
Ganci M, Pradel M, Hughes EK. Feasibility of a parent education and skills workshop for improving response to family-based treatment of adolescent anorexia nervosa. Int J Eat Disord. 2018;51(4):358–62.
Accurso EC, et al. Adaptation and implementation of family-based treatment enhanced with dialectical behavior therapy skills for anorexia nervosa in community-based specialist clinics. Eat Disord. 2018;26(2):149–63.
Peterson C, et al. FBT with adjunctive parent emotion coaching in an adolescent male with anorexia nervosa. Clin Case Stud. 2016;15(5):409–23.
Wagner I, et al. Attachment-based family therapy as an adjunct to family-based treatment for adolescent anorexia nervosa. Aust N Z J Fam Ther. 2016;37:207–27.
Hildebrandt T, et al. Exposure-based family therapy (FBT-E): An open case series of a new treatment for anorexia nervosa. Cogn Behav Pract. 2014;21:470–84.
Timko CA, et al. An open trial of Acceptance-based Separated Family Treatment (ASFT) for adolescents with anorexia nervosa. Behav Res Ther. 2015;69:63–74.
Hurst K, Zimmer-Gembeck M. Family-based treatment with cognitive behavioural therapy for anorexia. Clin Psychol. 2019;23:61–70.
Merwin RM, Zucker NL, Timko CA. A pilot study of an acceptance-based separated family treatment for adolescent anorexia nervosa. Cogn Behav Pract. 2013;20(4):485–500.
Hurst K, Zimmer-Gembeck M. Focus on perfectionism in female adolescent anorexia nervosa. Int J Eat Disord. 2015;48(7):936–41.
Hurst K, Read S, Holtham T. Bulimia nervosa in adolescents: a new therapeutic frontier. J Fam Ther. 2017;39(4):563–79.
Eisler I, et al. A pragmatic randomised multi-centre trial of multifamily and single family therapy for adolescent anorexia nervosa. BMC Psychiatry. 2016;16(1):422.
Gabel K, et al. The effect of multiple family therapy on weight gain in adolescents with anorexia nervosa: pilot data. J Can Acad Child Adolesc Psychiatry. 2014;23(3):196–9.
Hollesen A, Clausen L, Rokkedal K. Multiple family therapy for adolescents with anorexia nervosa: a pilot study of eating disorder symptoms and interpersonal functioning. J Fam Ther. 2013;35:53–67.
Salaminiou E, et al. Intensive multi-family therapy for adolescent anorexia nervosa: an open study of 30 families. J Fam Ther. 2017;39:498–513.
Gelin Z, et al. The effects of a multiple family therapy on adolescents with eating disorders: an outcome study. Fam Process. 2015;54(1):160–72.
Stewart C, et al. Multi-family therapy for bulimia nervosa in adolescence. Eat Disord. 2015;23(4):345–55.
Agras WS, et al. Comparison of 2 family therapies for adolescent anorexia nervosa: a randomized parallel trial. JAMA Psychiatry. 2014;71(11):1279–86.
Carr A, McDonnell D, Afnan S. Anorexia nervosa: the treatment of a male case with combined behavioural and family therapy. J Fam Ther. 1989;11:335–51.
Merl H. Systemic family therapy in a case of anorexia nervosa in a boy--a case report within the scope of final interventions. Psychother Psychosom Med Psychol. 1989;39(12):444–51.
De Benedetta G, et al. Cancer and anorexia nervosa in the adolescence: a family-based systemic intervention. Int J Family Med. 2011;2011:1–8.
Minuchin S, et al. A conceptual model of psychosomatic illness in children. Family organization and family therapy. Arch Gen Psychiatry. 1975;32(8):1031–8.
Wallin U, Kronvall P. Anorexia nervosa in teenagers: change in family function after family therapy, at 2-year follow-up. Nord J Psychiatry. 2002;56(5):363–9.
Combrinck-Graham L. Structural family therapy in psychosomatic illness. Treatment of anorexia nervosa and asthma. Clin Pediatr (Phila). 1974;13(10):827–33.
Liebman R, Minuchin S, Baker L. The role of the family in the treatment of anorexia nervosa. J Am Acad Child Psychiatry. 1974;13(2):264–74.
Godart N, et al. A randomized controlled trial of adjunctive family therapy and treatment as usual following inpatient treatment for anorexia nervosa adolescents. PLoS One. 2012;7(1):e28249.
Debow SL. Identical twins concordant for anorexia nervosa. A preliminary case report. Can Psychiatr Assoc J. 1975;20(3):215–7.
Lane D, Kern R. Multidimensional treatment of a 14-year-old anorexia nervosa patient. J Child Adolesc Psychother. 1987;4(3):211–5.
O’Halloran S. Family involvement in the treatment of anorexia nervosa: A solution-focused approach. Fam J. 1999;7(4):384–8.
Geist R, et al. Comparison of family therapy and family group psychoeducation in adolescents with anorexia nervosa. Can J Psychiatr. 2000;45(2):173–8.
Johnson S, Maddeaux C, Blouin J. Emotionally focused family therapy for bulimia: Changing attachment patterns. Psychotherapy. 1998;35(2):238–47.
Dalle Grave R, et al. Enhanced cognitive behaviour therapy for adolescents with anorexia nervosa: an alternative to family therapy? Behav Res Ther. 2013;51(1):R9–R12.
Cowdrey FA, Davis J. Response to enhanced cognitive behavioural therapy in an adolescent with anorexia nervosa. Behav Cogn Psychother. 2016;44(6):717–22.
Cooper PJ, Fairburn CG. Cognitive behaviour therapy for anorexia nervosa: some preliminary findings. J Psychosom Res. 1984;28(6):493–9.
Martin-Murcia F, Diaz A, Gonzalez L. A case study of anorexia nervosa and obsessive personality disorder using third-generation behavioral therapies. Clin Case Stud. 2011;10(3):198–209.
Heffner M, Sperry J, Eifert G, Detweiler M. Acceptance and commitment therapy in the treatment of an adolescent female with anorexia nervosa: a case example. Cogn Behav Pract. 2002;9:232–6.
Scrignar C. Food as the reinforcer in the outpatient treatment of anorexia nervosa. J Behav Ther Exp Psychiat. 1971;2:31–6.
Fundudis T. Anorexia nervosa in a pre-adolescent girl: a multimodal behaviour therapy approach. J Child Psychol Psychiatry. 1986;27(2):261–73.
Ollendick T. Behavioral treatment of anorexia nervosa: a five year study. Behav Modif. 1979;3(1):124–35.
Wildes JE, Marcus MD. Development of emotion acceptance behavior therapy for anorexia nervosa: a case series. Int J Eat Disord. 2011;44(5):421–7.
Pegado P, et al. Development, applicability, and effects of a pilot program of group cognitive-behavioral therapy in Brazilian adolescents with anorexia nervosa. Arch Clin Psychiatry. 2018;45(3):57–60.
Ohmann S, et al. Emotional aspects of anorexia nervosa: results of prospective naturalistic cognitive behavioral group therapy. Neuropsychiatr. 2013;27(3):119–28.
Stefini A, et al. Cognitive-behavioral and psychodynamic therapy in female adolescents with bulimia nervosa: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2017;56(4):329–35.
Dalle Grave R, et al. Transdiagnostic cognitive behaivour therapy for adolescents with an eating disorder who are not underweight. Behav Res Ther. 2015;73:79–82.
Lock J. Adjusting cognitive behavior therapy for adolescents with bulimia nervosa: results of case series. Am J Psychother. 2005;59(3):267–81.
Schapman-Williams AM, Lock J, Couturier J. Cognitive-behavioral therapy for adolescents with binge eating syndromes: a case series. Int J Eat Disord. 2006;39(3):252–5.
Cooper M, et al. Cognitive therapy for bulimia nervosa: an A-B replication series. Clin Psychol Psychother. 2007;14:402–11.
Anbar RD, Savedoff AD. Treatment of binge eating with automatic word processing and self-hypnosis: a case report. Am J Clin Hypn. 2005;48(2–3):191–8.
Schapman-Williams AM, Lock J. Using cognitive-behavioral therapy to treat adolescent-onset bulimia nervosa: a case study. Clin Case Stud. 2007;6(6):508–24.
Sysko R, Hildebrandt T. Enhanced cognitive behavioural therapy for an adolescent with purging disorder: a case report. Eur Eat Disord Rev. 2011;19(1):37–45.
Seigel L. Classical and operant procedures in the treatment of a case of food aversion in a young child. J Clin Child Psychol. 1982;11(2):167–72.
Chatoor I, Conley C, Dickson L. Food refusal after an incident of choking: a posttraumatic eating disorder. J Am Acad Child Adolesc Psychiatry. 1988;27(1):105–10.
Culbert TP, et al. Hypnobehavioral approaches for school-age children with dysphagia and food aversion: a case series. J Dev Behav Pediatr. 1996;17(5):335–41.
Chorpita BF, Vitali AE, Barlow DH. Behavioral treatment of choking phobia in an adolescent: an experimental analysis. J Behav Ther Exp Psychiatry. 1997;28(4):307–15.
Nock MK. A multiple-baseline evaluation of the treatment of food phobia in a young boy. J Behav Ther Exp Psychiatry. 2002;33(3–4):217–25.
Bailly D, et al. Choking phobia in childhood: a differential diagnosis with anorexia nervosa. Arch Pediatr. 2003;10(4):337–9.
Ciyiltepe M, Turkbay T. Phagophobia: a case report. Turk J Pediatr. 2006;48(1):80–4.
Okada A, et al. A study of psycho-pathology and treatment of children with phagophobia. Acta Med Okayama. 2007;61(5):261–9.
de Roos C, de Jongh A. EMDR treatment of children and adolescents with a choking phobia. J EMDR Pract Res. 2008;2(1):201–11.
Fischer A, Luiselli J, Dove M. Effects of clinic and in-home treatment on consumption and feeding-associatied anxiety in an adolescent with avoidant/restictive food intake disorder. Clin Pract Pediatr Psychol. 2015;3(2):154–66.
Murphy J, Zlomke K. A behavioral parent-training intervention for a child with avoidant/restrictive food intake disorder. Clin Pract Pediatr Psychol. 2016;4(1):23–34.
Reid DB. A case study of hypnosis for phagophobia: it’s no choking matter. Am J Clin Hypn. 2016;58(4):357–67.
Bloomfield B, et al. Treatment of food selectivity in a child with avoidant/restrictive food intake disorder through parent teleconsultation. Bahav Anal Prac. 2018;12:33.
Fitzpatrick K, et al. Adolescent focused psychotherapy for adolescents with anorexia nervosa. J Contemp Psychother. 2010;40:31–9.
Pharis M, Penn M. A model for outpatient treatment of young adolescents with anorexia nervosa. Child Adolesc Soc Work. 1984;1:34–48.
Prestano C, et al. Group analytic therapy for eating disorders: preliminary results in a single-group study. Eur Eat Disord Rev. 2008;16(4):302–10.
Fischer S, Peterson C. Dialectical behavior therapy for adolescent binge eating, purging, suicidal behavior, and non-suicidal self-injury: a pilot study. Psychotherapy (Chic). 2015;52(1):78–92.
Safer D, Lock J, Couturier J. Dialectical behavior therapy modified for adolescent binge eating disorder: a case report. Cogn Behav Pract. 2007;14:157–67.
Salbach-Andrae H, et al. Dialectical behavior therapy of anorexia and bulimia nervosa among adolescents: a case series. Cogn Behav Pract. 2008;15(4):415–25.
Dahlgren CL, et al. Neuropsychological functioning in adolescents with anorexia nervosa before and after cognitive remediation therapy: a feasibility trial. Int J Eat Disord. 2013;46(6):576–81.
van Noort BM, et al. Cognitive remediation therapy for children with anorexia nervosa. Z Kinder Jugendpsychiatr Psychother. 2015;43(5):351–5.
Carei TR, et al. Randomized controlled clinical trial of yoga in the treatment of eating disorders. J Adolesc Health. 2010;46(4):346–51.
Kafantaris V, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207–12.
Spettigue W, et al. Evaluation of the effectiveness and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescents: an open-label trial. J Can Acad Child Adolesc Psychiatry. 2018;27(3):197–208.
Norris ML, et al. Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):213–20.
Hillebrand JJ, et al. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry. 2005;58(8):651–7.
Swenne I, Rosling A. No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders. J Child Adolesc Psychopharmacol. 2011;21(3):221–7.
Leggero C, et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol. 2010;20(2):127–33.
Pisano S, et al. Second generation antipsychotics in adolescent anorexia nervosa: a new hypothesis of eligibility criteria. J Child Adolesc Psychopharmacol. 2014;24(5):293–5.
Dennis K, Le Grange D, Bremer J. Olanzapine use in adolescent anorexia nervosa. Eat Weight Disord. 2006;11(2):e53–6.
Boachie A, Goldfield GS, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord. 2003;33(1):98–103.
Mehler C, et al. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry. 2001;10(2):151–7.
La Via MC, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord. 2000;27(3):363–6.
Dadic-Hero E, et al. Olanzapine treatment in anorexia nervosa: case report. Psychiatr Danub. 2009;21(1):122–5.
Hein IM, Huyser C. Olanzapine in the treatment of adolescents with anorexia nervosa. Tijdschr Psychiatr. 2010;52(6):417–21.
Tateno M, et al. Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified. Psychiatry Clin Neurosci. 2008;62(6):752.
Ercan ES, et al. Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum Psychopharmacol. 2003;18(5):401–3.
Dodig-Curkovic K, et al. The case report of treatment strategy for anorexia nervosa with psychotic elements in adolescent. Coll Antropol. 2010;34(3):1093–9.
Ayyildiz H, et al. Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa. Eat Weight Disord. 2016;21(2):309–11.
Ritchie B, Norris ML. QTc prolongation associated with atypical antipsychotic use in the treatment of adolescent-onset anorexia nervosa. J Can Acad Child Adolesc Psychiatry. 2009;18(1):60–3.
Norris ML, et al. Factors influencing research drug trials in adolescents with anorexia nervosa. Eat Disord. 2010;18(3):210–7.
Bozabali O, Baykara B, Baykara A. Olanzapine use in five different psychiatric disorders in children and adolescents. Bull Clin Psychopharmacol. 2002;12(4):179–85.
Brewerton TD, D'Agostino M. Adjunctive use of olanzapine in the treatment of avoidant restrictive food intake disorder in children and adolescents in an eating disorders program. J Child Adolesc Psychopharmacol. 2017;27(10):920–2.
Hagman J, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50(9):915–24.
Fisman S, et al. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry. 1996;35(7):937–40.
Kracke EJ, Tosh AK. Treatment of anorexia nervosa with long-term risperidone in an outpatient setting: case study. Springerplus. 2014;3:706.
Umehara H, Iga J, Ohmori T. Successful treatment of anorexia nervosa in a 10-year-old boy with risperidone long-acting injection. Clin Psychopharmacol Neurosci. 2014;12(1):65–6.
Newman-Toker J. Risperidone in anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 2000;39(8):941–2.
Pennell A, et al. Severe avoidant/restrictive food intake disorder and coexisting stimulant treated attention deficit hyperactivity disorder. Int J Eat Disord. 2016;49(11):1036–9.
Mehler-Wex C, et al. Atypical antipsychotics in severe anorexia nervosa in children and adolescents--Review and case reports. Eur Eat Disord Rev. 2008;16(2):100–8.
Frank GK, et al. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord. 2017;50(4):447–50.
Frank GK. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-a case series. Int J Eat Disord. 2016;49(5):529–33.
Trunko ME, et al. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord. 2011;44(3):269–75.
Colak Sivri R, Hizarcioglu Gulsen H, Yilmaz A. Phagophobia successfully treated with low-dose aripiprazole in an adolescent: a case report. Clin Neuropharmacol. 2018;41(4):148–50.
Holtkamp K, et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res. 2005;39(3):303–10.
Frank GK, Kaye WH, Marcus MD. Sertraline in underweight binge eating/purging-type eating disorders: five case reports. Int J Eat Disord. 2001;29(4):495–8.
Lyles B, Sarkis E, Kemph JP. Fluoxetine and anorexia. J Am Acad Child Adolesc Psychiatry. 1990;29(6):984–5.
Gee RL, Telew N. Obsessive-compulsive disorder and anorexia nervosa in a high school athlete: a case report. J Athl Train. 1999;34(4):375–8.
Kotler LA, et al. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol. 2003;13(3):329–35.
Tor PC, Lee EL. Treatment emergent mania responding to valproate in a Chinese female adolescent population with eating disorders: a case series. Eur Eat Disord Rev. 2008;16(6):421–6.
Wolter H, et al. Diagnostic crossover from obesity to atypical anorexia nervosa - a case report. Obes Facts. 2009;2(1):52–3.
Banerjee SP, Bhandari RP, Rosenberg DR. Use of low-dose selective serotonin reuptake inhibitors for severe, refractory choking phobia in childhood. J Dev Behav Pediatr. 2005;26(2):123–7.
Hosoglu E, Akca OF. Escitalopram in the treatment of a 3-year-old child with posttraumatic feeding disorder. J Child Adolesc Psychopharmacol. 2018;28(2):153–4.
Celik G, et al. Fluoxetine in posttraumatic eating disorder in two-year-old twins. J Child Adolesc Psychopharmacol. 2007;17(2):233–6.
Hrdlicka M, et al. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study. Eur Child Adolesc Psychiatry. 2008;17(3):187–9.
Jaafar NR, et al. Mirtazapine for anorexia nervosa with depression. Aust N Z J Psychiatry. 2007;41(9):768–9.
Naguy A, Al-Mutairi A. An adolescent male with anorexia nervosa favorably responded to mirtazapine. Am J Ther. 2018;25(6):e675–6.
Gray E, et al. Mirtazapine and weight gain in avoidant and restrictive food intake disorder. J Am Acad Child Adolesc Psychiatry. 2018;57(4):288–9.
Tanidir C, Herguner S. Mirtazapine for choking phobia: report of a pediatric case. J Child Adolesc Psychopharmacol. 2015;25(8):659–60.
Anis N, Isomaa R, Kaltiala-Heino R. Adolescent psychiatric inpatients with first hospitalization due to anorexia nervosa: can rehospitalization be predcited by clinical features. Psychiatr Fenn. 2016;47:76–94.
Ayton A, Keen C, Lask B. Pros and cons of using the mental health act for severe eating disorders in adolescents. Eur Eat Disord Rev. 2009;17(1):14–23.
Castro-Fornieles J, et al. Predictors of weight maintenance after hospital discharge in adolescent anorexia nervosa. Int J Eat Disord. 2007;40(2):129–35.
Fennig S, et al. Inpatient treatment has no impact on the core thoughts and perceptions in adolescents with anorexia nervosa. Early Interv Psychiatry. 2017;11(3):200–7.
Goddard E, et al. A multi-centre cohort study of short term outcomes of hospital treatment for anorexia nervosa in the UK. BMC Psychiatry. 2013;13:287.
Heinberg LJ, et al. Clinical course and short-term outcome of hospitalized adolescents with eating disorders: the success of combining adolescents and adults on an eating disorders unit. Eat Weight Disord. 2003;8(4):326–31.
Kalisvaart JL, Hergenroeder AC. Hospitalization of patients with eating disorders on adolescent medical units is threatened by current reimbursement systems. Int J Adolesc Med Health. 2007;19(2):155–65.
Leon GR, et al. Sexual, body-image, and personality attitudes in anorexia nervosa. J Abnorm Child Psychol. 1985;13(2):245–57.
Lievers LS, Curt F, Wallier J, Perdereau F, Rein Z, Jeammet P, Godart N. Predictive factors of length of inpatient treatment in anorexia nervosa. Eur Child Adolesc Psychiatry. 2009;18(2):75–84.
Mekori E, et al. Predictors of short-term outcome variables in hospitalised female adolescents with eating disorders. Int J Psychiatry Clin Pract. 2017;21(1):41–9.
Morris J, Simpson AV, Voy SJ. Length of stay of inpatients with eating disorders. Clin Psychol Psychother. 2015;22(1):45–53.
Nova E, Lopez-Vidriero I, Varela P, Casas J, Marcos A. Evolution of serum biochemical indicators in anorexia nervosa patients: a 1-year follow-up study. J Hum Nutr Diet. 2007;21:23–30.
Roux H, et al. Predictive factors of dropout from inpatient treatment for anorexia nervosa. BMC Psychiatry. 2016;16(1):339.
Schlegl S, et al. Inpatient treatment for adolescents with anorexia nervosa: clinical significance and predictors of treatment outcome. Eur Eat Disord Rev. 2016;24(3):214–22.
Shugar G, Krueger S. Aggressive family communication, weight-gain, and improved eating attitudes during systemic family-therapy for anorexia-nervosa. Int J Eat Disord. 1995;17(1):23–31.
Tasaka K, et al. Long-term follow up of hospitalized pediatric anorexia nervosa restricting type. Pediatr Int. 2017;59(4):482–9.
Treat TA, et al. Treatment of anorexia nervosa in a specialty care continuum. Int J Eat Disord. 2008;41(6):564–72.
Vall E, Wade TD. Predictors and moderators of outcomes and readmission for adolescent inpatients with anorexia nervosa: a pilot study. Clin Psychol. 2017;21(2):143–52.
Bourion-Bedes S, et al. Prognostic value of early therapeutic alliance in weight recovery: a prospective cohort of 108 adolescents with anorexia nervosa. J Adolesc Health. 2013;52(3):344–50.
Rothschild-Yakar L, Lacoua L, Stein D. Changes in patient measures as predictors of therapists’ ratings of treatment collaboration and change in eating disorder subgroups. Assessment. 2013;20(6):752–63.
Toms DA, Crisp AH. Weight phobia in an adolescent male with stunted development. J Psychosom Res. 1972;16(4):289–95.
Strik Lievers L, Curt F, Wallier J, Perdereau F, Rein Z, Jeammet P, Godart N. Predictive factors of length of inpatient treatment in anorexia nervosa. Eur Child Adolesc Psychiatry. 2009;18(2):75–84.
Avnon A, et al. Inpatient weight curve trajectory as a prognostic factor among adolescents with anorexia nervosa: a preliminary report. Eat Weight Disord. 2018;23(5):645–51.
Hetman I, et al. Percentage from target weight (PFTW) predicts re-hospitalization in adolescent anorexia nervosa. Isr J Psychiatry Relat Sci. 2017;54(3):28–34.
Singer L, et al. Cognitive-behavioural treatment of health-impairing food phobias in children. J Am Acad Child Adolesc Psychiatry. 1992;31(5):847–52.
Pitt PD, Middleman AB. A focus on behavior management of avoidant/restrictive food intake disorder (ARFID): a case series. Clin Pediatr (Phila). 2018;57(4):478–80.
Rhodes P, Prunty M, Madden S. Life-Threatening Food Refusal in Two Nine-Year-Old Girls: Re-Thinking the Maudsley Model. Clin Child Psychol Psychiatry. 2009;14(1):63–70.
Halvorsen I, et al. Naturalistic outcome of family-based inpatient treatment for adolescents with anorexia nervosa. Eur Eat Disord Rev. 2018;26(2):141–5.
Paul P, Mehta S, Coffey BJ. Anorexia nervosa in a 14-year-old second-generation hispanic adolescent boy. J Child Adolesc Psychopharmacol. 2013;23(4):295–9.
Salbach-Andrae H, et al. Short-term outcome of anorexia nervosa in adolescents after inpatient treatment: a prospective study. Eur Child Adolesc Psychiatry. 2009;18(11):701–4.
Leitenberg H, Agras WS, Thomson LE. A sequential analysis of the effect of selective positive reinforcement in modifying anorexia nervosa. Behav Res Ther. 1968;6(2):211–8.
Blinder BJ, Freeman DM, Stunkard AJ. Behavior therapy of anorexia nervosa: effectiveness of activity as a reinforcer of weight gain. Am J Psychiatry. 1970;126(8):1093–8.
Garfinkel PE, Kline SA, Stancer HC. Treatment of anorexia nervosa using operant conditioning techniques. J Nerv Ment Dis. 1973;157(6):428–33.